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Abstract

ANALYZING THE FUNCTIONS OF HUMAN POLYNUCLEOTIDE PHOSPHORYLASE
(hPNPaseold-35)
By Upneet Kaur Sokhi, M.Sc.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2013
Major Advisor: Dr. Paul B. Fisher, M.Ph., Ph.D.
Professor and Chair, Department of Human and Molecular Genetics

RNA degradation plays a fundamental role in maintaining cellular homeostasis,
along with being a part of normal regulatory mechanisms, whether it occurs as a
surveillance mechanism eliminating aberrant mRNAs or during RNA processing to
generate mature transcripts. 3’-5’ exoribonucleases are essential mediators of RNA
decay pathways, and one such evolutionarily conserved enzyme is polynucleotide
phosphorylase (PNPase). The human homologue of this fascinating enzymatic protein
(hPNPaseold-35) was cloned a decade ago in the context of terminal differentiation and
senescence through a novel ‘overlapping pathway screening’ approach. Since then,
significant insights have been garnered about this exoribonuclease and its repertoire of
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expanding functions. hPNPaseold-35 has progressed a long way from being just a 3’-5’
exoribonuclease to a functionally relevant molecule implicated in a multitude of diverse
and important biological effects. hPNPaseold-35 plays central roles in diverse
physiological processes including growth inhibition, senescence, mtRNA import,
mitochondrial homeostasis, and RNA degradation, all while primarily being localized in
the mitochondrial IMS (inter membrane space). hPNPaseold-35 also holds immense
promise as a therapeutic agent due to its ability to degrade specific miRNA (miR-221)
and mRNA (c-myc) species, and this property can be exploited in treating malignancies
that are characterized by upregulation of harmful miRNA or mRNA molecules. But apart
from these two targets, little is known about any other targets hPNPaseold-35 may
degrade. Thus, the primary objective of this dissertation research was to identify targets
other than c-myc or miR-221 that hPNPaseold-35 could directly degrade to discover
newer and biologically relevant therapeutic targets for the treatment of hPNPaseold-35 –
associated disease states. In order to do this we performed extensive microarray
analyses following hPNPaseold-35 overexpression and depletion in mammalian cell lines,
and were able to identify transcripts that could be potentially regulated by hPNPaseold-35
directly or indirectly. Apart from this we also analyzed the 3’UTR of c-myc in order to
identify any specific sequence or secondary structural elements necessary for
hPNPaseold-35 mediated degradation. Lastly, we identified certain residues in
hPNPaseold-35 that have been under positive natural selection through evolution.

CHAPTER ONE

INTRODUCTION
Part of the work presented in this chapter has been published in Advances in Cancer
Research 119:161-90 (2013).
1.1 RNA degradation pathways
Post-transcriptional control of gene expression occurs at multiple steps that
include mRNA processing, its export from the nucleus to cytoplasm, mRNA localization,
mRNA stability, translational regulation and finally mRNA decay [1]. A number of
evolutionarily conserved trans-acting regulatory factors have been identified over the
past years that are involved in each of these steps [2,3]. Previously, RNA degradation
was thought to be a random process, but studies over the past few years have proved
quite the contrary. It is a well-controlled process involving the interplay of a number of
proteins working together and contributing to the maintenance of cellular homeostasis
[4]. Two major pathways have been identified for eukaryotic mRNA turnover,
deadenylation-dependent

decay

and

deadenylation-independent

decay

[5-7].

Deadenylation-dependent decay is usually triggered by the presence of certain ciselements in the mRNA sequence such as AU-rich elements in the 3’UTR and instability
elements in the coding region [8,9]. The first step in this process is the shortening of the
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poly(A) tail or deadenylation, which is brought about by certain deadenylases like the
Ccr4/Pop2/NOT complex, Pan2/Pan3 or PARN [poly(A) ribonuclease]. Following this
process, the mRNA can undergo 3’-5’ decay by the exosome, which is a complex of 3’5’ exoribonucleases or PNPase (a phosphorolytic 3’-5’ exoribonuclease), with the
residual cap structure being hydrolysed by the scavenger enzyme DcpS or 5’-3’
exonucleolytic digestion by an exonuclease Xrn1p after decapping by the Dcp1/Dcp2
enzyme complex [8,10]. Deadenylation-independent decay, mostly consisting of RNA
surveillance mechanisms, may occur when there is a premature stop codon in the
mRNA sequence (Nonsense-mediated decay or NMD) in which case 5’-3’ digestion
occurs after removal of the cap structure by the same enzymes discussed earlier [7,11].
In the event of an absence of a termination codon (Nonstop decay or NSD), the
aberrant mRNA is recognized and degraded in a 3’-5’ manner by the exosome. When
there is a stall in translation elongation (No-go decay or NGD), cleavage occurs at the
stall site by an endonuclease (IME1, PMR1 or RNase MRP) after which the fragments
are digested by the 3’ and 5’ exoribonucleases [11]. These processes are summarized
in Fig. 1.1.
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Fig. 1.1. RNA decay mechanisms. A diagrammatic representation of various RNA
degradation pathways. Refer to text for details.
	
  

1.2 Exoribonucleases
Ribonucleases (RNases) are the main players involved in RNA metabolism,
performing important roles in RNA maturation, RNA end-turnover and in the degradation
of aberrant RNAs or species no longer required by the cell [12]. Based on their
degradative properties, they are classified into exo- and endo-ribonucleases, with
exoribonucleases being further classified into 5’-3’ and 3’-5’ exoribonucleases
depending on the direction of degradation [13]. Eukaryotes possess both these classes
of enzymes whereas prokaryotes like E. coli lack the 5’-3’ exoribonuclease activity.
Extensive sequence homology studies have culminated in the various exoribonucleases
in all kingdoms to be grouped into the following superfamilies (with representative
	
  

3	
  

	
  
examples from E.coli and some of their eukaryotic homologues): the RBN (RNase BN)
family present only in eubacteria, the RNR (RNase II, RNase R, Rrp44, Dss I, Ssd I),
DEDD (RNase D, RNase T, oligoribonuclease, Rrp6, Pan2, Rex1-4),and PDX (Rnase
PH, PNPase, Rrp41-43, 45, 46, Mtr3) families present in bacteria, archaea and
eukaryotes, the RRP4 (Rrp4, 40, Csl4) family present in archaea and eukaryotes and
lastly the 5PX (Xrn1, Rat1) family present only in eukaryotes [14,15]. RNA degradation
by most exoribonucleases occurs via hydrolytic cleavage of the 3’ phosphodiester bond
to generate nucleotide monophosphates, but certain members like PNPase and RNase
PH do so through a phosphorolytic mechanism that utilizes inorganic phosphate to
generate nucleotide diphosphates [4].
1.3 PNPase
Polynucleotide

phosphorylase

(PNPase)

is

an

evolutionarily

conserved

phosphorolytic 3’-5’ processive exoribonuclease that is present in all phyla extending
from bacteria, plants, worms and flies, to mice and humans, although it is absent in
fungi, trypanosomes and Archaea [13]. Studies in E.coli have shown that in the
presence of high inorganic phosphate (Pi), this enzyme acts exclusively as an
exoribonuclease, whereas in the event of low Pi, it acts as a polymerase resulting in the
elongation of the poly(A) tail by adding nucleotides and generating Pi. PNPase was
discovered by Severo Ochoa and Marianne Grunberg-‐Manago in 1955 and Ochoa
received the Nobel Prize in 1959 for discovering its polymerizing activity [4,16]. The
human homologue of PNPase (hPNPaseold-35) was first identified as a gene that was
upregulated in terminally differentiated human melanoma cells and senescent progeroid
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fibroblasts in an ‘overlapping pathway screen’ to identify differentially regulated genes in
the context of terminal differentiation and senescence (Fig. 1.2) [17].

Fig. 1.2. Identification of human PNPase. Schematic representation of the
overlapping pathway screen that aided in the identification of transcripts
upregulated in the processes of terminal differentiation and senescence.
	
  

1.3.1 PNPase structure
PNPase from all diverse species share a classical domain structure that contains
a catalytic PDX domain characteristic of all PDX family members [13,18]. Almost all
PNPases are composed of five conserved structural motifs; the amino-terminal domain
is composed of 2 RNase PH domains, an α-helical domain that separates the RNase
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PH domains, and 2 carboxy-terminal RNA-binding domains KH (K-homology) and S1
[13,18-20] (Fig. 1.3).

Fig. 1.3. Domain organization of PNPases from different species. PNPases from
humans, plants and bacteria showing the presence of two conserved catalytic
RNasePH domains and two RNA binding domains KH and S1.	
  
In plants, PNPase is translocated to the chloroplast stroma or mitochondrial
matrix by an N-terminal chloroplast-transit peptide (cTP) or a mitochondrial-targeting
sequence (MTS), respectively [21]. Human PNPase (hPNPaseold-35), a 783 amino acid
long ~86 kDa protein, also contains an N-terminal MTS that allows its primary location in
the cell to be the mitochondria, where it assembles into a homotrimer or a dimer of two
homotrimers [22,23]. PNPase from the bacterium Streptomyces antibioticus was the
first to be crystallized; it was observed that it forms a homotrimeric doughnut shaped
structure with a central channel formed by the 6 RNase PH domains containing the
catalytic sites and through which a single-stranded RNA molecule can enter [20,24].
Extensive deletion and mutation studies have been done in the past decade to
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understand the structural specificities of the phosphorolytic and RNA-binding properties
of PNPase. The catalytic activity of the bacterial PNPase resides mainly in the second
RNase PH domain, which also seems to possess RNA binding ability as demonstrated
by a G454D mutation, but both domains are required for proper enzymatic activity [25].
In bacteria, deletion of the KH or S1 domain reduces the specific activity of the enzyme
by ~19- or ~50-fold, respectively, whereas deleting both domains reduces the enzymatic
activity to ~1% [26]. X-ray crystallography studies using E.coli full-length and KH/S1
truncated PNPase further elucidated that the KH and S1 domains are important for
proper trimer formation apart from RNA binding along with certain conserved residues in
the first RNase PH domain that are important for proper RNA binding and processive
degradation [27]. In case of plants, chloroplast PNPase exists as a homo-multimer [28]
and both its RNase PH domains possess phosphorolytic and polymerizing activities
[21]. Mutation analysis of human PNPase showed that it possesses similar
phosphorolytic properties to its homologues in different species, with both the RNase
PH domains possessing equal enzymatic activity, and the presence of either one of
them being sufficient for complete enzymatic activity as shown in our studies [29].
However, there are some differences in its RNA-binding affinities compared to other
species of PNPases [30]. Also, human PNPase still retains enzymatic activity after
deletion of both the KH and S1 domains in contrast to its bacterial homologue, which
further strengthens the observation that the RNase PH domains may also play a role in
RNA binding after all [29].
More recent advances in understanding the structural evolution of this interesting
exoribonuclease come from the successful crystallization of an S1-domain truncated
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human PNPase [31]. This study reveals a slight difference between the bacterial and
human PNPases, in that the S1 domain was found to be dispensable for RNA binding
and the 3 KH domains formed a pore on top of the homotrimer (formed by the 6 RNase
PH domains), which in turn is solely responsible for binding RNA through its conserved
GXXG motif [31]. Although this is an exciting finding, it stands in contrast to previously
published reports as mentioned earlier, that the RNase PH domains also possess RNA
binding ability [29]. Future studies crystallizing the full length and maybe a KH domain
truncated human PNPase may provide useful insights into the workings of this intriguing
protein.
1.3.2 PNPase, degradosome, exosome
Apart from existing as an individual entity in the cytoplasm, PNPase is also found
as part of a multiprotein complex associated with endonuclease RNase E, the DEADbox helicase RhlB and enolase, a glycolytic enzyme in bacteria [32-36]. This structure is
called the degradosome and contains approximately 20% of the total PNPase present in
the bacterial cell [37]. Yeast contains a similar multiprotein complex consisting of
exoribonucleases called the exosome present in the nucleus and the cytoplasm, from
which PNPase is absent [38,39]. The yeast exosome is made up of 8 exoribonucleases
(Rrp6p, Rrp41-46p and Mtr3p) with some of them sharing homology with bacterial
RNase PH and 3 RNA binding subunits (Rrp4p, Rrp40p and Csl4p) [40]. All of the yeast
exosome subunits have human homologues, except Rrp43p and Mtr3p [19,41]. There is
high structural homology between the eukaryotic exosome and homotrimeric PNPase,
both looking like ring-shaped structures with a central catalytic core channel through
which the RNA molecule enters for degradation [24], although recent studies have
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shown that human PNPase possesses a KH pore versus a S1 pore in exosomes that
facilitates RNA-binding [31].
1.4 Identification and regulation of hPNPaseold-35 expression
Human PNPase is encoded by the gene PNPT1 mapping to chromosome 2p152p16.1, consisting of 28 exons and spanning ~60 kb on the reverse strand [42]. It was
first identified as a gene that was upregulated in senescent progeroid fibroblasts and
terminally differentiated HO-1 human melanoma cells in a quest to recognize molecular
mediators controlling cellular senescence and differentiation that would aid in
improvement of cancer therapy [17]. Human melanoma is a well-established model for
studying differentiation therapy of cancer and terminal differentiation, which can be
induced by combined treatment with recombinant human fibroblast interferon (IFN)-β
and protein kinase C activator mezerein (MEZ), resulting in similar phenotypic
characteristics as cellular senescence. These findings formed the basis for a screening
strategy intended to identify overlapping gene expression changes associated with both
terminal differentiation and senescence (Fig. 2). cDNA from terminally differentiated
HO-1 cells was used to generate a differentiation-induction subtraction hybridization
(DISH) library, which was screened with a probe generated from the mRNA of
senescent progeroid fibroblasts [17,43]. Of the 75 genes identified through this
screening approach designated old-1 to old-75, old-35 was one of the identified cDNAs
that showed an elevated expression associated with both terminal differentiation and
senescence [17]. old-35 exhibited substantial sequence homology to PNPase from
other species and was thus identified as human polynucleotide phosphorylase or
hPNPaseold-35. hPNPaseold-35 is expressed in all primary tissues [17] and a PNPT1
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knockout mouse is embryonic lethal, indicating its importance in early mammalian
development [44].
Bacterial PNPase has been shown to autocontrol its own expression at the posttranscriptional level by binding and degrading part of a stem-loop structure in its own
mRNA 5’-leader sequence cleaved by RNase III, subsequently resulting in mRNA
instability and reduced expression [45]. On the other hand, not much is known about the
transcriptional or post-transcriptional regulation of hPNPaseold-35, except that it is
induced by type I interferons (IFN-α and -β) at the transcription level in both normal and
cancer cells [42]. Since type I interferons are cytokines secreted by cells in response to
viral infections, it could be speculated that hPNPaseold-35 may play a role in the cell’s
antiviral response through its RNA processing function. Induction of hPNPaseold-35
mRNA, which has a half-life of ~6h [42], was evident even with 1 U/ml of IFN-β and as
early as 3 hrs in HO-1 cells (2000 U/ml IFN-β), demonstrating that it is an early IFN
response gene [17] (Fig. 1.4).
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Fig. 1.4. Regulation of hPNPaseold-35 expression by IFN-β. (A) Induction of
hPNPaseold-35 mRNA by IFN-β post 24 hours in melanoma cell lines. (B) IFN-β induces
hPNPaseold-35 protein resulting in downregulation of c-myc post 48hours in melanoma
cell lines.	
  

IFN-γ and TNF-α treatment resulted in minimal or no induction, whereas poly(I)/poly(C),
which induces IFN-α and -β, also stimulated hPNPaseold-35 expression [17]. Promoter
characterization experiments and sequence analysis resulted in the identification of an
IFN-stimulated response element (ISRE) in the hPNPaseold-35 promoter, to which the
ISGF3 complex shows increased binding upon IFN-β treatment [42]. Mutating this site
abrogated promoter induction, demonstrating that IFN-β is a transcriptional activator of
hPNPaseold-35 whose activation depends on the JAK/STAT signal transduction pathways
[42]. In silico analysis of the hPNPaseold-35 promoter has highlighted several additional
transcription factor binding sites, but at present any connection of these regulatory
elements to physiological conditions relating to hPNPaseold-35 expression remains to be
determined [46]. In any case, it would be relevant to determine if there are other
regulatory factors controlling hPNPaseold-35 expression levels and future endeavors
towards achieving this goal are required to better understand hPNPaseold-35 functions.
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1.5 Subcellular Localization of hPNPaseold-35
Human PNPase possesses a mitochondrial-targeting signal (MTS) at its amino
terminus. Immunofluorescence and cell fractionation studies demonstrated that
endogenous and C-terminal myc-tagged hPNPaseold-35 localizes exclusively to the
mitochondria [22]. It was expected that the location was obviously mitochondrial matrix,
where an enzyme like hPNPaseold-35 was predicted to perform mitochondrial RNA
processing analogous to its bacterial and chloroplast counterparts. However,
subsequent research involving subfractionation studies, protease protection assays and
carbonate extraction experiments proved that hPNPaseold-35 is actually a peripheral
inner membrane (IM) - bound protein located in the mitochondrial inter membrane
space (IMS) [47] and is imported to this location via an i-AAA protease Yme1-dependent
mechanism [23]. hPNPaseold-35 first enters through the TOM complex at the outer
mitochondrial membrane, and this is followed by its N-terminus extending through the
TIM23 complex at the inner mitochondrial membrane into the matrix, enabling its
cleavage by the matrix-processing peptidase (MPP). Yme1 localized at the inner
membrane first facilitates release of the N-terminus into the IMS followed by pulling the
C-terminus of hPNPaseold-35 across the TOM complex into the IMS [23]. While these
studies are quite convincing, the topic of hPNPaseold-35 subcellular localization has been
controversial, as our studies involving ectopic overexpression of hPNPaseold-35 have
shown that it localizes to both the mitochondria and cytoplasm. In our overexpression
studies, N-terminal GFP-tagged hPNPaseold-35 was found to localize to the cytoplasm
[17], which is consistent with the findings of Chen et al [18]. This observation might be
due to blockage of the N-terminal MTS, although we did not see an effect of this on the
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growth inhibitory effects of hPNPaseold-35. C-terminal HA-tagged hPNPaseold-35 on the
other hand localizes both in the mitochondria and cytoplasm as documented in our
studies. There may be shuttling mechanisms that facilitate the transport of hPNPaseold35

from the mitochondrial IMS to the cytoplasm, like the one suggested by Chen et al.

where hPNPaseold-35 migrated to the cytoplasm after mitochondrial outer membrane
(OM) permeabilization [47], thus allowing it to degrade certain mRNA and miRNA
species as reported previously in our studies [48,49]. Conversely physiological
conditions allowing OM permeabilization or RNA import pathways could also allow RNA
substrates to enter the IMS and subsequently get processed by hPNPaseold-35 [44,50].
Recently, hPNPaseold-35 has also been found in the nucleus of breast cancer cells
exposed to ionizing radiation where it interacts with nuclear EGFR [51]. Further studies
are required to establish whether this is a global or cell line and condition specific
phenomena. Based on all this information it would be safe to say hPNPaseold-35 may
have distinct roles based on its specific localization in distinct cellular compartments.
1.6 Functions of hPNPaseold-35
1.6.1 hPNPaseold-35, growth inhibition, senescence and RNA degradation
As mentioned earlier, hPNPaseold-35 was first identified as a gene that was
upregulated in senescent progeroid fibroblasts and terminally differentiated HO-1
human melanoma cells [17]. Both senescence and terminal differentiation share certain
common characteristics like irreversible growth arrest notably occurring in the G1 phase
of the cell cycle, with inhibition of both DNA synthesis and telomerase activity [52-54].
To elucidate the functional link between a 3’-5’ exoribonuclease like hPNPaseold-35 and
phenomena like senescence and terminal differentiation, replication-incompetent
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adenoviral mediated hPNPaseold-35-overexpression (Ad.hPNPaseold-35) studies were
performed [48]. (Fig. 1.5)

Fig. 1.5. Adenoviral-mediated hPNPaseold-35 overexpression causes inhibition
of cellular proliferation of HO-1 cells. (A)	
  HO-1 cells were infected with Advec or
Ad.hPNPaseold-35 at an m.o.i. of 5000vp/cell. 6 hrs later, the cells were trypsinized,
counted and 1000 cells were plated per 6-cm dish (in triplicate). Colony numbers
were determined after 3 weeks. (B) Graphical representation of colony numbers.
	
  

It was observed that slow and sustained overexpression of hPNPaseold-35 results in
inhibition of growth of multiple cells types and induces a senescent-like phenotype in
HO-1 human melanoma cells and normal human melanocytes, ultimately resulting in
apoptosis [29,48]. The morphological features evident after about 5 days of adenoviral
infection in HO-1 cells are very similar to terminally differentiated HO-1 cells treated with
IFN-β and mezerein for the same period of time, which is accompanied by inhibition of
telomerase activity [48]. In separate studies, normal human melanocytes stained
positive for SA-β-gal, a well known biochemical marker for senescence, and
morphologically resembled cells entering a senescent stage by becoming large and
flattened after Ad.hPNPaseold-35 infection [48]. This senescence-like phenotype could
also be mediated by adenoviral overexpression of either of the 2 RNase PH domains of
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hPNPaseold-35 alone, which was confirmed by deletion studies of the full-length protein
[29]. Cell cycle analysis of different cell lines infected with Ad.hPNPaseold-35 showed an
initial G1/S or G2/M arrest with inhibition of DNA synthesis followed by induction of
apoptosis [48,55]. This was accompanied by gene expression changes resembling
those occurring during terminal differentiation and senescence, including upregulation of
CDKI p27Kip1 levels and decreases in CDKI p21CIP1/WAF-1/MDA-6 levels, both of which play
significant roles in cell cycle arrest [48]. On the other hand, rapid overexpression of
hPNPaseold-35 rapidly promotes apoptosis without any cell-cycle changes, implying that
multiple intracellular targets and signaling pathways are involved in hPNPaseold-35mediated inhibition of cell-cycle progression and apoptosis.
1.6.2 Molecular mechanisms of growth inhibition and senescence: Interestingly,
some light was shed on one of the molecular mechanisms of hPNPaseold-35-induced
growth-inhibition and senescence when it was observed that Ad.hPNPaseold-35
overexpression could downregulate c-myc mRNA and protein expression [48].
Interestingly, its expression is downregulated during both terminal differentiation of HO1 melanoma cells and senescence. Myc is an important transcription factor that
regulates numerous physiological processes like cellular growth and proliferation,
metabolism and apoptosis [56]. It is one of the key mediators that play a role in
transition of cells from the G1 to S phase of the cell cycle and is known to control p27Kip1
expression

by

multiple

mechanisms.

Rescue

experiments

involving

ectopic

overexpression of c-myc CDS (coding sequence) significantly protected HO-1 cells from
Ad.hPNPaseold-35 mediated cell death, confirming that one mechanism by which
Ad.hPNPaseold-35 causes growth inhibition is by downregulating c-myc expression (Fig.
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5) [48]. However, since c-myc overexpression provided only partial protection from
Ad.hPNPaseold-35-mediated cell death, there might be other pathways involving genes
that may be direct targets of hPNPaseold-35 degradation, which is an interesting avenue
of investigation we are currently pursuing. Interestingly, in a recent study breast cancer
cells resistant to ionizing radiation had higher levels of c-myc mRNA. This was
attributed to an inactive form of hPNPase which was phosphorylated at S776 in the
nucleus by nEGFR-regulated DNAPK, resulting in its inability to degrade c-myc mRNA
[51].
The mechanism by which hPNPaseold-35 mediates apoptosis has also been
identified and is attributed to its ability to activate double-stranded RNA (dsRNA)dependent protein kinase (PKR) and phosphorylation of eIF-2α. Activation of PKR
results in induction of GADD153 and a decrease in the levels of the anti-apoptotic
protein Bcl-xL, ultimately culminating in apoptosis [57].
Inhibition of growth by IFN-β is also characterized by downregulation of c-myc
expression, which it is known to regulate post-transcriptionally [58,59]. hPNPaseold-35
induction following IFN-β treatment has also been shown to downregulate c-myc mRNA
and miR-221 levels, implicating its important role in IFN-β-mediated growth inhibition
[49,60]. The role of hPNPaseold-35 in IFN-β-mediated growth inhibition is further
strengthened by the finding that transient or stable knockdown of hPNPaseold-35 in
melanoma cells makes them resistant to IFN-β-mediated cell death [60]. IFN-β has also
been shown to reduce mitochondrial RNA levels [61], which can be another mechanism
by which IFN-β-induced hPNPaseold-35 plays a role in growth inhibition via its RNA
degrading activity (Fig. 5) [22].
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1.6.3 RNA degradation by hPNPaseold-35: In vitro mRNA degradation assays further
validated that full-length hPNPaseold-35 or either of its two RNase PH domains can
specifically degrade c-myc mRNA, whereas other mRNAs like c-jun, GAPDH or
GADD34 are not affected (Fig. 5) [29,48]. The exact mechanism of how hPNPaseold-35
specifically recognizes and degrades c-myc mRNA is still not clear, although our initial
belief was that this may be mediated by a specific sequence in the 3’UTR of c-myc
mRNA (as 3’UTRs contain various instability elements that act as important
determinants of RNA turnover [62,63], as c-myc RNA devoid its 3’UTR was resistant to
hPNPaseold-35 degradation [48,60]. Also, no specific RNA-binding site has been
described in PNPase from any other species either, which is further confounded by the
fact that in E.coli PNPase degrades a family of CSP (Cold-shock proteins) that do not
show any sequence similarity [64]. Recent advances in studies involving substrate
recognition by exoribonucleases have shown that RNA secondary structural elements
may be primary determining factors in RNA binding and degradation rather than primary
sequence. Future studies involving bioinformatics approaches and/or deletion/mutation
analysis of c-myc 3’UTR mRNA sequence are required to better understand the
importance of secondary structural elements in c-myc mRNA that allow its selective
degradation by hPNPaseold-35.
1.6.4 miRNA regulation by hPNPaseold-35: miRNAs are small, single-stranded, noncoding RNAs, ~19-25 nucleotides in length that bind to a specific recognition sequence
in the 3’UTR of their target mRNAs by complementary base pairing ultimately resulting
in their cleavage and degradation or translational repression [65]. Genes encoding
miRNAs have been found to be located in intergenic regions, within introns of protein
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coding genes and also within introns and exons of non-protein coding genes [66]. They
are transcribed in the nucleus by RNA polymerase II or III as primary or pri-miRNA
consisting of a 60-80 nucleotide long stem loop structure. Precursor or pre-miRNA is
generated by cleavage of pri-miRNA by an RNase complex DROSHA/DGCR8, which is
then transported to the cytoplasm by Exportin-5. Further cleavage by an RNase Dicer
results in the biogenesis of a double-stranded ~22 nucleotide miRNA which finally yields
the mature miRNA after unwinding and stabilization by the Argonaute proteins [65,67].
Regulation of gene expression by microRNAs was first discovered in C. elegans
in 1993 and since then numerous miRNAs have been identified in plants and animal
cells. The deregulation of miRNAs in various cancers and diseases has made them an
active avenue of study that holds potential possibilities of therapeutic intervention [65].
Stemming from this interest, recently our group identified another novel mechanism by
which hPNPaseold-35 causes growth inhibition by playing a significant role in posttranscriptional modification of miRNA biogenesis [49,67]. In the quest to further
understand hPNPaseold-35 functions as an exoribonuclease, a miRNA Microarray
analysis performed after Ad.hPNPaseold-35 infection of melanoma cells resulted in the
identification of specific miRNAs that were differentially regulated by hPNPaseold-35.
Subsequent validation of downregulated miRNAs through immunoprecipitation,
quantitative RT-PCR, northern blotting analysis and in vitro degradation assays showed
that hPNPaseold-35 could specifically bind and degrade certain mature miRNAs like miR221, miR-222 and miR-106b, while having no effect on others like miR-184 and miRlet7a (Fig. 6) [49]. Also, this downregulation by hPNPaseold-35 was limited to mature
miRNAs only, primary and precursor miRNA were not affected, establishing a novel
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hPNPaseold-35-mediated

post-transcriptional

regulatory

mechanism

of

miRNA

biogenesis. Apart from hPNPaseold-35 adenoviral overexpression studies, treatment of
different melanoma cell lines with IFN-β (that induces hPNPaseold-35) also resulted in
downregulation of miR-221 without having an effect on miR-184 or miR-let7a, which
further strengthens the authenticity of this phenomenon in a more physiological setting.
On the other hand, IFN-β treatment was unable to downregulate miR-221 in melanoma
cells in which hPNPaseold-35 was knocked down and conversely, overexpression of miR221 made HO-1 cells resistant to IFN-β-mediated growth arrest. Interestingly, miR-221
is a negative regulator of the p27Kip1 mRNA and accordingly this was identified as
another pathway through which hPNPaseold-35 suppresses growth by downregulating
miR-221 resulting in a subsequent increase in p27Kip1 levels (Fig. 6) [49]. The specific
binding of hPNPaseold-35 to defined miRNAs can be sequence or secondary structure
related, and this hypothesis needs to be further tested.
1.6.5 hPNPaseold-35 and inflammation
A characteristic feature of aging is chronic inflammation, which is also a hallmark
of progressive degenerative diseases like Parkinson’s disease (PD), amyotrophic lateral
sclerosis (ALS), atherosclerosis, Alzheimer’s disease (AD) and type 2 diabetes [68,69].
Aging is a phenomenon that is studied extensively, but at this point not a lot is known
about the relationship between cellular senescence and inflammation. Damage that is
caused by oxidative stress plays an important role in aging-associated inflammation,
which is evident in tissues collected from aged individuals or aged experimental animals
in the form of oxidative damage in their DNA, protein and lipids [70,71]. One of the
important generators of reactive oxygen species (ROS) in the cell is mitochondria which
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cause cumulative oxidative damage over time [68]. ROS have been known to regulate
activity of the transcription factor NF-κB, which can turn on the expression of proinflammatory cytokines like IL-6, IL-8, RANTES and MMP-3 [72,73]. In our adenoviral
overexpression studies we found that hPNPaseold-35 localization in the mitochondria
plays an important role in inducing ROS that leads to degradation of IκB-α, followed by
nuclear translocation of the p65 subunit of NF-κB and increased p50/p65 NF-κB DNA
binding resulting in increased production of pro-inflammatory cytokines as mentioned
earlier [74,75]. The anti-oxidant N-acetyl-L-cysteine (NAC) could inhibit all of these
events linked to aging-related inflammation, but does not protect cells from hPNPaseold35

-induced growth inhibition [13,74]. Since hPNPaseold-35 expression is elevated during

senescence and Ad. hPNPaseold-35 infection increases ROS production in the
mitochondria (one possibility being that ROS could be generated as a result of
mitochondrial protein turnover of hPNPaseold-35-substrates [76-78], a hypothesis that
needs to be further tested), we can conclude that mitochondria-localized hPNPaseold-35
plays a role in regulating the inflammatory components of senescence [74,79] . Also,
given that hPNPaseold-35 is an early type I IFN-responsive gene and activation of IFNsignaling pathway leading to the upregulation of IFN-regulated genes have been
documented during the process of senescence [17,42,80] , these findings indicate that
IFN might play an important role in regulating inflammatory diseases of aging [79].
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1.7 Functions of hPNPaseold-35 in mitochondria
1.7.1 hPNPaseold-35 and mitochondrial homeostasis: The subcellular localization of
hPNPaseold-35 in mitochondria has led to numerous studies aimed at trying to
comprehend the role of hPNPaseold-35, if any in maintaining mitochondrial homeostasis
and this has been done by classical gene knockdown and overexpression studies. The
level of hPNPaseold-35 knockdown seems to play a critical role in deciding the
observable changes in mitochondrial physiology and function [47,50]. An ~75%
reduction in hPNPaseold-35 levels in HEK293T cells caused mitochondria to become
filamentous and granular shaped, along with a three- to four-fold decrease in
mitochondrial membrane potential (∆Ψ) and enzymatic activities of coupled respiratory
complexes I and III, coupled complexes II and III, and individual complexes IV and V of
the respiratory chain, accompanied by secondary changes like lactate accumulation and
reduction of steady-state ATP levels [47]. Contradictory data is also available that
shows no change in mitochondrial morphology or function in HeLa cells after
hPNPaseold-35 knockdown [76]. Recent in vivo data representing a more physiological
setting, has confirmed a role for hPNPaseold-35 in the maintenance of mitochondrial
homeostasis, wherein mitochondria of liver-specific PNPT1 knockout mice show
disordered, circular and smooth cristae along with a 1.5-2 fold decrease in activity of
respiratory chain complex IV and complexes II+III+IV [44].
Overexpression of hPNPaseold-35 is found to cause an increase in ROS
accumulation over time [74], which could be due to increased respiratory chain activity
caused by mitochondrial dysfunction and implicates a role of hPNPaseold-35 in
mitochondrial homeostasis maintenance. An exoribonuclease-independent role of
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hPNPaseold-35 has also been highlighted in some studies wherein overexpressed
hPNPaseold-35 plays a role in protecting cells from oxidized forms of RNA by limiting
them from the translation mechanism [81,82].
1.7.2 hPNPase and RNA import into mitochondria: Different RNA import pathways
have been identified in various organisms but not much is known about the components
involved [83,84]. New advances continue to be made, with one of the recent discoveries
being the involvement of PNPase in regulating translocation of RNA into the
mitochondria. It has been recently reported that PNPase regulates the import of
nucleus-encoded small RNAs including RNase P RNA, MRP RNA, and 5S rRNA into
the mitochondrial matrix by binding to specific stem-loop motifs in the imported RNAs
[44,50]. Supporting this evidence is the proof that liver-specific PNPT1 knockout mice
mitochondria showed a significant reduction in the RNA component of the RNase P
mtRNA complex [44]. It should also be noted that PNPase mutations that inactivate
RNA processing do not affect RNA import implying that these two functions are
independent of each other. How PNPase makes the decision between RNA processing
versus import is still an area that requires further experimentation [44,50].
1.7.3 Role of hPNPase in mtRNA processing: Polyadenylation plays an important
role in mtRNA metabolism and depending on the organism can lead to quick decay or
increased stability of the transcript [85,86]. In contrast to bacteria and some eukaryotes
where polyadenylation is catalyzed by poly(A) polymerases (PAPs) or PNPase, human
mtRNA is polyadenylated by mitochondria-specific PAP. In order to answer the question
whether hPNPase acts as a polymerase or exoribonuclease in mitochondria, it was
silenced by shRNA treatment which resulted in an increase in the length of poly(A) tails
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of mtRNA without having any effect on steady state levels of these mRNA species
[47,76]. Another group showed that stable silencing of hPNPase had varied effects on
different mt-mRNAs, and that polyadenylation of mtRNAs is performed by a polymerase
distinct from both mtPAP and PNPase [87]. It is also suggested that hPNPase silencing
causes ATP depletion which can alter the length of mtRNA polyI(A) tails [76,87]. Other
studies suggest a role for hPNPase in complex with hSUV3 (human suppressor of Var1
3) acting as degradation complex acting on double-stranded RNA in mammalian
mitochondria, which hypothesizes a role for hPNPase in mitochondrial RNA degradation
[78,88]. This degradation activity is suppressed by the LRPPRC/SLIRP (leucine-rich
pentatricopeptide repeat motif-containing protein/ stem-loop-interacting RNA-binding
protein) complex, which also promotes polyadenylation of mRNAs in the mitochondria
[89]. In the light of all this information, it is clear that a lot more needs to be resolved
before a clear picture of the role of hPNPase in mtRNA processing can be depicted
(Fig. 1.6).
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Fig. 1.6. Functions of hPNPaseold-35. hPNPaseold-35 is transcriptionally induced by
the JAK/STAT pathway through IFN-β produced by the cell after viral infection,
exposure to tumor cells, senescence-inducing signals or terminal-differentiation
promoting signals. Next, hPNPaseold-35 is imported to the mitochondrial inner
membrane space (IMS) by a YME- mediated mechanism or alternatively mobilized
through an unknown mechanism to the cytoplasm where it causes growth arrest or
apoptosis by targeting c-myc mRNA and miR-221 or activating PKR, respectively.
Exposure to ionizing radiation inactivates hPNPaseold-35 by an EGFR-mediated
mechanism, causing c-myc mRNA upregulation and increasing radioresistance of
cancer cells. In the mitochondria hPNPaseold-35 maintains mitochondrial homeostasis,
aids in RNA import, takes part in mtRNA processing/degradation events and
increases ROS production that results in events leading to chronic inflammation.
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CHAPTER TWO

Gene Expression Signature of Human Polynucleotide Phosphorylase (hPNPaseold35
) in Melanoma cells
Part of the work presented in this chapter has been published in PLoS One 8(10):
e76284 (2013).

2.1 Abstract
Human Polynucleotide Phosphorylase (hPNPaseold-35 or PNPT1) is an
evolutionarily conserved 3’→5’ exoribonuclease implicated in the regulation of
numerous

physiological

processes

including

maintenance

of

mitochondrial

homeostasis, mtRNA import and aging-associated inflammation. From an RNase
perspective, little is known about the RNA or miRNA species it targets for degradation
or whose expression it regulates, except for c-myc and miR-221. To further elucidate
the functional implications of hPNPaseold-35 in cellular physiology, we knocked-down and
overexpressed hPNPaseold-35 in human melanoma cells and performed gene expression
analyses to identify differentially expressed transcripts. Ingenuity Pathway Analysis
indicated that knockdown of hPNPaseold-35 resulted in significant gene expression
changes associated with mitochondrial dysfunction and cholesterol biosynthesis,
whereas overexpression of hPNPaseold-35 caused global changes in cell-cycle related
functions. Additionally, comparative gene expression analyses between our hPNPaseold-
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knockdown and overexpression datasets allowed us to identify 77 potential “direct”

and 61 potential “indirect” targets of hPNPaseold-35 which formed correlated networks
enriched for cell-cycle and wound healing functional association, respectively. These
results provide a comprehensive database of genes responsive to hPNPaseold-35
expression levels, along with the identification of new potential candidate genes offering
fresh insight into cellular pathways regulated by PNPT1 which may be used in the future
for possible therapeutic intervention in mitochondrial- or inflammation-associated
disease phenotypes.
2.2 Introduction
Ribonucleases (RNases) are one of the central players involved in the regulation
of post-transcriptional control of gene expression in both prokaryotes and eukaryotes
[12,37]. They are divided into two main categories, endo- and exo-ribonucleases.
Depending on the direction of degradation, exoribonucleases can be further classified
as 5’→3’ or 3’→5’ exoribonucleases [90]. Numerous exoribonucleases identified in
bacteria, Archaea and Eukarya have been placed under six major superfamilies, RBN,
RNR, DEDD, PDX, RRP4 and 5PX [4,14]. Of these, the PDX family is the only one
whose members use inorganic phosphate to generate nucleotide diphosphates instead
of hydrolytic cleavage [14]. Polynucleotide phosphorylase (PNPase) is an evolutionarily
conserved phosphorolytic 3’→5’ exoribonuclease that belongs to the PDX family of
proteins [4] and it plays a major role in RNA metabolism in bacteria, plants and humans.
The protein encoded by this gene consists of five conserved classical domains: two
RNase PH domains, a α–helical domain and two RNA binding domains KH and S1 [91].
The human homolog of this gene (hPNPaseold-35) was identified in an overlapping
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pathway screen (OPS) intended to identify upregulated transcripts in terminally
differentiated human melanoma cells and senescent progeroid fibroblasts [17].
Human polynucleotide phosphorylase (hPNPaseold-35) is encoded by the PNPT1
gene mapping to chromosome 2p15-2p16.1 and has been characterized as a type I IFN
(IFN-α/β)-inducible early response gene [17,42]. Numerous endeavors over the past
decade have enriched our comprehension of the workings of this exoribonuclease. It
has become increasingly clear over the years that the various physiological functions of
this enzymatic protein are not restricted to a single cellular compartment, in this case
the mitochondrial inter membrane space (IMS) where it is primarily located [23,47]. In
the cytoplasm this protein performs a myriad of functions, which include but are not
restricted to degradation of mRNA and miRNA species [48,49]. Adenoviral-mediated
overexpression of hPNPaseold-35 causes growth inhibition of normal and cancer cells
characterized by morphological changes associated with senescence, G1/S or G2/M
cell-cycle arrest and apoptosis [48,55,57,92]. The ability of hPNPaseold-35 to selectively
degrade c-myc mRNA through its exoribonucleolytic activity has been identified as a key
molecular mechanism mediating the growth suppressive effects of hPNPaseold-35, since
overexpression of c-myc could only partially rescue these effects [48].

Apart from

mRNA degradation, hPNPaseold-35 has also been identified as a direct regulator of
mature miRNA species, specifically miR-221 that targets the cell cycle inhibitor p27Kip1
[49,67]. Both these specialized functions of hPNPaseold-35 also implicate it as a direct
mediator of IFN-β-induced growth inhibition [49,60]. Another novel function of
hPNPaseold-35 is its ability to generate double-stranded RNA (dsRNA) through a currently
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unknown mechanism, which ultimately leads to apoptosis of cells due to the activation
of dsRNA-dependent protein kinase (PKR) [57].
Apart from the above-mentioned cytoplasmic functions that focus on its
physiological roles in the regulation of growth inhibition and senescence, numerous
roles of hPNPaseold-35 have been revealed that are central to its location in the
mitochondria [13,67,75,93]. Overexpression of hPNPaseold-35 induces reactive oxygen
species (ROS) production in the mitochondria resulting in the expression of proinflammatory cytokines, which is a major phenomenon linking hPNPaseold-35 to agingrelated inflammation [74,79]. The significance of hPNPaseold-35 in maintaining
mitochondrial homeostasis, with a specific relevance to the electron transport chain
(ETC) components, has been revealed by hPNPaseold-35 knockdown studies in cell
systems and also in a liver-specific knockout mouse model of hPNPaseold-35 [44,47].
There are also studies providing evidence that hPNPaseold-35 is a regulator of
mitochondrial RNA import and plays a role in mtRNA processing [44,50,51,76,87].
Recently hPNPaseold-35 has also been shown to be present in the nucleus, and is
associated with nEGFR protein, which regulates the exoribonuclease activity of
hPNPaseold-35 upon exposure to ionizing radiations [75].
Most of what we know about hPNPaseold-35 today has been gleaned from
classical gain-of-function or loss-of-function experiments and from comparative studies
performed through lessons acquired from its bacterial and plant counterparts [13,67,93].
Although these studies have been immensely valuable in illuminating the importance of
hPNPaseold-35 in various physiological phenomena like senescence, growth-inhibition
and mitochondrial dynamics, little is known about the specific network of genes that are
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involved in these processes or which might be dysregulated when hPNPaseold-35 is
aberrantly expressed. Moreover, when evaluating its function as an exoribonuclease,
we know of only one mRNA and a single miRNA species that hPNPaseold-35 can
degrade directly, c-myc and miR-221, respectively. Such findings led to our interest in
trying to identify genes or gene networks that are either potential direct degradation
targets of hPNPaseold-35 or regulated by hPNPaseold-35, respectively. In order to pursue
this objective, we performed gene expression analysis on human melanoma cells in
which hPNPaseold-35 was either silenced or ectopically overexpressed. Studying the
global gene expression changes associated with hPNPaseold-35-knockdown or
overexpression has provided valuable new insights regarding the functions of this
elusive exoribonuclease while also validating previously known information. With the
help of Ingenuity Pathway Analysis (IPA) we have identified key biological functions and
associated genes that are deregulated in response to aberrant expression of
hPNPaseold-35. Additionally, comparative analysis of the knockdown and overexpression
datasets has allowed us to identify novel genes that may be directly or indirectly
regulated by hPNPaseold-35.
In summary, our present studies interrogated the global implications of
hPNPaseold-35 dysregulation and now provide a comprehensive database that can be
further used not only to understand the biological functions of hPNPaseold-35 but also to
identify candidate direct degradation targets such as c-myc and miR-221.
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2.3 Materials and methods
2.3.1 Cell culture
The human melanoma cell line HO-1 [53,95,96] was initially provided by Dr.
Eliezer Huberman (Argonne National Laboratories, IL) maintained in Dulbecco’s
Modified Eagle Medium (DMEM; Invitrogen Life Technologies) supplemented with 10%
fetal bovine serum (FBS; Sigma) and 5% penicillin/streptomycin (Gibco). The melanoma
cell line WM35 [96-99], provided by Dr. Meenhard Herlyn (Wistar Institute) was
maintained in MCDB153:Leibovitz’s L15 (4:1) pH 7.4 supplemented with 2% FBS and
CaCl2 (1.68mM, Sigma). The hPNPaseold-35-knockdown stable cell lines were
maintained in growth medium as described with the addition of 200 ng/ml (in case of
HO-1 cells) or 300 ng/ml (in case of WM35 cells) of the selective antibiotic puromycin.
All cell lines were maintained in a 5% CO2 95% O2 humidified incubator at 37°C. 0.5%.
Trypsin-EDTA (10X) solution was purchased from Gibco and 1X Dulbecco’s PhosphateBuffered Saline (DPBS) from Corning Cellgro.
2.3.2 Expression constructs, stable cell lines and viral infections
Lentiviral constructs (pGIPZ) expressing GFP were purchased from Open
Biosystems. The constructs contained non-silencing short hairpin RNA (shRNA) or
shRNAs against hPNPaseold-35 (PNPshRNA-1: clone ID V2LHS_17644, Mature Sense:
GGCAACAGGAAATTAGAAA,

Mature

Antisense:

TTTCTAATTTCCTGTTGCC;

PNPshRNA-2: clone ID V2LHS_159887, Mature Sense: CAATAGGATTGGTCACCAA,
Mature Antisense: TTGGTGACCAATCCTATTG). Lentiviruses encoding the different
shRNAs were produced by cotransfecting the HEK-293T packaging cells with the
appropriate pGIPZ constructs and the Trans-lentiviral Packaging Mix (Open
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Biosystems) according to the manufacturer’s protocol. The supernatants containing the
lentiviral particles were harvested 48 hours after transfection, concentrated by
centrifugation and frozen at -80°C as aliquots. 1ml of the above viral suspension was
used to transduce 3 x 105 HO-1 human melanoma cells grown in 6-cm dishes
supplemented with 10 µg/ml polybrene. 48 hours post-transduction cells were
trypsinized and replated at a low density (1:5) and complete media was added
supplemented with positive selection marker puromycin to establish stable shRNA
expressing single clones over a period of two weeks. Single clones isolated for
PNPshRNA-1 and PNPshRNA-2 were screened to assess the level of knockdown at
both the RNA and protein levels and the HO-1 clones with maximum hPNPaseold-35
knockdown were used for microarray analyses (we used one of our HO-1 PNPshRNA-1
clones for this purpose).
The construction and purification of replication-incompetent adenovirus encoding
hPNPaseold-35 (Ad.hPNPaseold-35) has been described previously [17,48]. The empty
vector Ad.vec was used as a control. For all adenoviral experiments, 1 x 105 cells were
grown in 6-cm dishes and infected after 24 hours with Ad.vec or Ad.hPNPaseold-35 at a
final m.o.i. of 5000 vp/cell diluted in 1 ml of serum-free media. After 6 hours of infection
with shaking every 15 minutes, complete media was added and cells were harvested at
the required time points (e.g., 36 hours post-infection) for microarray analysis, RNA or
protein isolation.
All

transient

transfections

were

performed

using

Lipofectamine®

2000

Transfection Reagent (Life Technologies) according to the manufacturer’s protocol.
RNA and protein were harvested 48hrs post-transcfection for all experimental analyses.
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2.3.3 RNA extraction, quality assessment and Microarray analyses
Total RNA from the hPNPaseold-35-knockdown cell line (HO-1 melanoma cells
stably expressing shRNA-1 against hPNPaseold-35), HO-1 cells expressing non-silencing
control shRNA, and HO-1 cells infected with Ad.hPNPaseold-35 or Ad.vec for 36 hours
was isolated from cell lysates in TRIZOL reagent (InvitrogenTM Life Technologies,
Carlsbad, CA). Cell lysates were subjected to an automated extraction method using
the MagMAX™-96 for Microarrays Total RNA Isolation Kit (Ambion/InvitrogenTM Life
Technologies, Carlsbad, CA) on the MagMAX™ Express Magnetic Particle Processor
(Applied Biosystems/InvitrogenTM LifeTechnologies, Carlsbad, CA).
Gene expression profiles were ascertained using GeneChip® Human Genome
U133A 2.0 (HG-U133A 2.0) arrays (Affymetrix, Santa Clara, CA) as previously
described [100]. Every chip was scanned at a high resolution, with pixelations ranging
from 2.5 µm down to 0.51 µm, by the Affymetrix GeneChip® Scanner 3000 according to
the GeneChip® Expression Analysis Technical Manual procedures (Affymetrix, Santa
Clara, CA). After scanning, the raw intensities for every probe were stored in electronic
files (in .DAT and .CEL formats) by the GeneChip® Operating Software (GCOS)
(Affymetrix, Santa Clara, CA). The overall quality of each array was assessed by
monitoring the 3′/5′ ratios for a housekeeping gene (GAPDH) and the percentage of
“Present” genes (%P); where arrays exhibiting GAPDH 3′/5′ < 3.0 and %P > 40% were
considered good quality arrays [100]. All experiments were done in biological triplicates.
The microarray data generated for this study are available online at the Gene
Expression Omnibus repository under the accession number GSE46884.
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2.3.4 Statistical Analysis, IPA and functional classification of genes
The Robust Multiarray Average method (RMA) was used for normalization and
generating probe set expression summaries for the gene expression assays. To identify
genes significantly altered among the different conditions (i.e., hPNPaseold-35 downregulation and up-regulation), t-tests were performed for each cell type. To adjust for
multiple hypothesis testing, the resulting p-values were used to obtain the false
discovery rates using the q-value method. Genes were considered significant using an
FDR of 5%. All analyses were performed in the R statistical environment using functions
provided by the BioConductor packages [100,101].
In order to categorize biological functions related to gene expression altered by
hPNPaseold-35 in our microarray analyses, we used the Ingenuity Pathway Analysis (IPA,
Ingenuity® Systems, http://www.ingenuity.com) [102,103]. Genes were considered
differentially expressed if they had q-values ≤ 0.05. The Affymetrix probe set IDs of
significantly altered genes identified through the statistical analysis described above in
both the hPNPaseold-35-knockdown and overexpression scenarios, along with their
associated p- and q-values were uploaded into IPA and analyses performed.
The ToppFun function of the ToppGene suite of web applications [104] was used
for the functional enrichment of the hPNPaseold-35-directly and indirectly regulated
genes. The HGNC symbols for both the gene lists were uploaded and a FDR correction
threshold of 5% was set for the subsequent functional enrichment analyses. The Gene
Ontology (GO) categories (molecular function, biological process, and cellular
component), biological pathway and gene and miRNA families were considered for
analyses.
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In order to further validate if genes regulated by alterations in hPNPaseold-35
expression formed gene interaction networks, the gene symbols for the potential
hPNPaseold-35-“directly”

and

-“indirectly”

regulated

genes

were

uploaded

into

GeneMANIA (http://www.genemania.org), a web interface for generating interactive
functional association networks [105]. This resource utilizes multiple external datasets,
including protein-protein interactions and published microarray datasets, to form
networks of potential gene-gene interactions. The interactive functional association
networks obtained were generated based on co-expression, biological pathways,
predicted association, genetic interactions, physical interactions and co-localization
functional association data. The networks were generated using the query-dependent
automatically selected weighting method.
2.3.5 cDNA synthesis and quantitative real-time RT-PCR (qRT-PCR)
Total RNA was harvested from the hPNPaseold-35-knockdown and control stable
cell lines and from the adenovirus infected HO-1 cells using the RNeasy purification kit
(Qiagen). The quality and concentrations of isolated RNA samples were assessed using
the NanoDrop 2000 (Thermo Scientific). 2 µg of RNA was used in a total volume of 20
µl to synthesize cDNA using the High Capacity cDNA Reverse Transcription kit (Applied
Biosystems) according to the manufacturer’s instructions. Real-time quantitative PCR
was conducted using the ViiATM 7 Real-Time PCR System (Applied Biosystems) and
performed in a total volume of 20 µl that contained the TaqMan Gene Expression
Master Mix (Applied Biosystems), 1 µl of the cDNA template generated and the targetspecific TaqMan Gene expression assays (Applied Biosystems) according to following
cycle parameters: 95°C for 10 minutes followed by 40 cycles at 95°C for 15 seconds
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and at 60°C for 1 minute. Each sample was run in triplicate using three biological
replicates and normalized to the housekeeping gene GAPDH used as an internal
control in each case. The ΔΔCt method was used for comparing relative fold expression
differences in the genes of interest between different test samples. Statistical
significance (P<0.05) was determined using two-tailed student’s t-test and one-way
analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test wherever
required.
2.3.6 Protein isolation and Western blot analysis
Cells were harvested by centrifugation, pellets washed in PBS and subsequently
lysed in ice-cold 1X cell lysis buffer (Cell Signaling) supplemented with PhosSTOP
Phosphatase Inhibitor Cocktail Tablets and complete Mini Protease Inhibitor Cocktail
Tablets (Roche), followed by centrifugation at 13,000 rpm for 15 minutes at 4°C. The
supernatant or whole cell lysate was collected in a fresh tube and protein concentration
was measured using the Bio-Rad Protein Assay Dye Reagent Concentrate (BIO-RAD).
30 µg of total cell lysate was mixed with SDS sample buffer and heated for 5 minutes at
95°C. The proteins were separated by 8-10% SDS-PAGE gels and transferred onto
nitrocellulose membranes and blocked using 5% non-fat milk supplemented with 1%
bovine serum albumin (BSA) in TBS-T for 1 hour. After washing three times with TBS-T
for 10 minutes each, the membranes were incubated with primary antibodies overnight
at 4°C. The primary antibodies used were anti-hPNPaseold-35 (chicken; 1:5000), antiEF1α (mouse, 1:1000). The next day membranes were washed as before and
incubated with the relevant horseradish-peroxidase conjugated secondary antibodies for
1 hour at room temperature. After washing three times with TBS-T for 10 minutes each,
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the proteins were detected using ECL Western Blotting detection reagent (GE
Healthcare Life Sciences) and exposed to X-ray film.
2.3.7 Invasion assay
Cellular invasion was determined using a modified a Boyden chamber (BD
BioCoatTM MatrigelTM Invasion Chambers (MIC) BD Biosciences, Catalog # 354480) by
plating 5x104 HO-1 Csh or HO-1 PNPsh1 cl4/cl17 into cell well inserts in a 24-well plate
provided by the manufacturer and according to the manufacturer’s instructions. After an
incubation of 48 hrs at 37°C in the presence of 5% CO2 using DMEM (without serum) in
both the top and bottom chambers; the number of cells that invaded through the
matrigel were fixed with Solution A (fixative) for five minutes, which is a component of
the Diff-Stain Kit (IMEB INC., Catalogue # K7148-2); next the wells were washed with
water and the non-invading cells trapped in the matrigel layer were removed with the
help of a cotton swab. The wells then were stained with Solution B (Azure stain) for 5-6
minutes and counterstained with Solution C (xanthenes dyes) for 5-6 minutes. Finally
the wells were lightly washed with water, dried and observed under the microscope.
Five 10X fields were chosen randomly and the average number of invaded cells were
counted. The data are represented as mean ± standard error of two independent
experiments done in duplicate. Statistical significance (P≤0.05) was determined by oneway analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test (Prism,
GraphPad, San Diego, CA, USA).
2.3.8 Immunohistochemistry
The multiple malignant melanoma tissue array slides with adjacent normal skin
tissue
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purchased

from

US

Biomax
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#

ME241a)

and

	
  
immunohistochemistry was performed. The slides were incubated at 60°C for 1 hour in
a vacuum chamber, followed by de-paraffination with two changes of xylene (5 minutes
each). Next the slides were rehydrated with gradient alcohol, 100%, 95%, 80% and 70%
for 3 minutes each, followed by incubating in water and PBS (phosphate buffer saline)
for 5minutes each. Antigen retrieval was performed by incubating the slides in warm
(95°C) Citrate-based antigen unmasking solution (Vector Laboratories, Inc., Catalogue
# H-3300) in a vacuum chamber for 1 hour. Next the slides were rinsed in PBS for 5
minutes and incubated in 2% H2O2 in PBS for 20 minutes. The slides were then blocked
with 5% goat serum in PBS-T (0.1% Tween-20 in PBS) for 1 hour at room temperature
and incubated with primary antibodies (anti-hPNPaseold-35 : chicken, 1:400; anti-EMR1:
rabbit polyclonal (Origene, Catalogue # TA308395), 1:200) diluted in blocking buffer
overnight at 4°C. The negative controls were also incubated in blocking buffer without
any primary antibodies. The next day the slides were rinsed with PBS thrice for 5
minutes each and incubated with biotinylated secondary antibodies (anti-chicken IgG,
Catalogue # BA-9010, anti-rabbit IgG, Catalogue # BA-1000, 1:500, Vector
Laboratories, Inc.) diluted in 2% goat serum in PBS-T for 1 hour at room temperature.
Next the slides were rinsed with PBS thrice for 5 minutes each and incubated with
VECTASTAIN® ABC reagent (Vector Laboratories, Inc.) for 30 minutes. After this the
slides were washed with PBS thrice for 5 minutes each and incubated with freshly
prepared ImmPACT DAB Peroxidase Substrate (Vector Laboratories, Inc., Catalogue #
SK-4105) for 1-5 minutes. The slides were rinsed with water, counterstained with
Hematoxylin QS nuclear counterstain (Vector Laboratories, Inc., Catalogue # H-3404)
and rinsed with water again for 5-10 minutes. The slides were then dehydrated with
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gradient alcohol, 70%, 80%, 95% and 100%, each 2-3 minutes, cleaned with xylene for
5 minutes, dried and mounted with coverslip after addition of 1 drop of VectaMount™
Mounting Medium (Vector Laboratories, Inc., Catalogue #H-5000) and viewed under
microscope.
2.4 Results
2.4.1 Melanoma cell culture model for studying hPNPaseold-35 regulated gene
expression
In order to establish stable HO-1 human melanoma cell lines in which
hPNPaseold-35 expression was silenced, we employed a lentiviral system to ensure
efficient delivery. RNA and protein levels of hPNPaseold-35 were analyzed in the different
single clones that survived after puromycin selection as described. Both the shRNAs
tested, PNPshRNA-1 (data shown for clone 4) and PNPshRNA-2 (data shown for clone
9), resulted in ≥80% and ~70% knockdown at the protein level as calculated by
densitometric analysis(Fig. 2.1.A) relative to the scrambled control shRNA respectively.
PNPshRNA-1 clone 4 was used for microarray analysis. The replication-deficient
adenovirus for ectopic overexpression of hPNPaseold-35 has been extensively
characterized previously [17,48]. Infection of HO-1 cells was performed as previously
described [17,48] and both RNA and protein were analyzed for overexpression of
hPNPaseold-35 (Fig. 2.1.B). RNA and protein from these cells were collected 36 h postinfection for microarray analysis and a >30 fold increase in hPNPaseold-35 RNA levels
and a 3 fold increase (as calculated by densitometric analysis) in hPNPaseold-35 protein
levels was observed in the Ad.hPNPaseold-35 compared to the Ad.Vec treated cells.

	
  

38	
  

	
  

Fig. 2.1. (A) Phase contrast LM (top) and GFP fluorescent micrographs (bottom) of
HO-1 melanoma cell lines following transduction with GFP expressing scrambled
shRNA and hPNPaseold-35 shRNA1 and 2 expressing lentiviruses and selection with
puromycin. qRT-PCR expression of hPNPaseold-35 normalized to control
(shScramble). Mean values normalized to a GAPDH internal reference; error bars
represent mean ± S.E. of three replicate experiments, statistical significance was
determined using one-way analysis of variance followed by Dunnett’s multiple
comparison test. Anti-hPNPaseold-35 and EF1α loading control immunoblots and
densitometric analysis graphically representing protein fold decrease. (B) qRT-PCR
expression of hPNPaseold-35 in HO-1 cells infected with Ad.hPNPaseold-35 normalized
to cells infected with Ad.Vec for 36 hour. Error bars represent mean ± S.E of three
replicate experiments, statistical significance was determined using student’s t-test.
Immunoblot showing hPNPaseold-35 overexpression compared to Ad.Vec post 36 hour
of infection and densitometric analysis showing protein fold increase.
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2.4.2 Genetic profile of hPNPaseold-35-knockdown melanoma cells
In order to further understand and possibly identify novel functions of hPNPaseold35

, we stably depleted it using shRNA in HO-1 human melanoma cells (Fig. 2.1.A). The

ability to study changes in gene expression patterns has become a valuable technique
that permits evaluation of the significance of a gene in a more global context. Microarray
analysis between the hPNPaseold-35 shRNA and the scrambled shRNA expressing HO-1
cells led to the identification of a total of 1025 upregulated and 1364 downregulated
transcripts which were altered significantly (FDR ≤ 0.05) (Fig. 2.2.B-C).

Fig. 2.2. Venn diagrams representing number of genes significantly altered when
hPNPaseold-35 is knocked down or overexpressed in human melanoma cells: Shown
are total number of dysregulated genes (A), genes “directly” (B) and “indirectly” (C)
regulated by hPNPaseold-35.
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We utilized IPA to functionally categorize all the differentially expressed genes
identified following hPNPaseold-35 knockdown in HO-1 melanoma cells. The main
molecular and cellular functions (p-values ranging from 3.92E-32 - 1.26E-03) associated
with the most significantly altered genes were cell death and survival, cellular growth
and proliferation, protein synthesis, cell cycle and RNA post-translational modification
(Fig. 2.3, Table S1A). Based on these functional categories 25 biological gene networks
were generated by IPA with a score ranging from 41 to 28 (Table S1D). IPA computes
scores for each network based on p-values, which in turn indicate the likelihood of
genes being found together in a network due to random chance. Higher the score,
lesser the chance of the genes in a network being grouped together by random chance
alone.

Fig. 2.3. The biological functions and states associated with genes differentially
expressed when hPNPaseold-35 is knocked down in human melanoma cells as
identified by IPA.
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Apart from classifying individual genes into functional categories, IPA also predicts
corresponding biological pathways that may be significantly altered, along with
mechanisms related to toxicity at a more biochemical level (Fig. 2.4).

Fig. 2.4. Toxicologically related functionalities and pathways associated with genes
dysregulated (proportions shown in graphs) after hPNPaseold-35 knockdown in
melanoma cells, as identified by IPA Toxicogenomic Analysis.	
  
The most significant canonical pathways identified were related to EIF2 signaling,
cholesterol biosynthesis, integrin signaling and mitochondrial dysfunction (Fig. 2.5,
Table S1C).
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Fig. 2.5. Canonical pathways associated with genes differentially expressed when
hPNPaseold-35 is knocked down in human melanoma cells.
	
  

Even more fascinating was the finding that two of these biological pathways, cholesterol
biosynthesis (Table 2.1) and mitochondrial dysfunction (Table 2.2), were directly
correlated with predicted physiological toxicity (identified through IPA-Tox analysis) (Fig.
2.4, Table S1B). HMGCR (Fig. 2.6.A), HMGCS1 and IDI1 were the three most
significantly altered genes belonging to the cholesterol biosynthesis pathway. An overall
downregulation of genes belonging to the electron transport chain and some associated
factors was observed, consistent with previous observations regarding the role of
hPNPaseold-35 in maintaining mitochondrial homeostasis [9,23]. Some of the significantly
downregulated genes were NDUFA3, NDUFS1, UQCRFS1, COX6B1, C0X7A1,
ATP5C1, CAT and UCP2 (Fig. 2.6.B).
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Table 2.1. List of genes which are significantly altered as a result of hPNPaseold-35
stable knockdown, and are associated with cholesterol biosynthesis, according to IPA
Toxicogenomic Analysis. FDR≤0.05 = *, FDR≤0.01 = **, FDR≤0.005 = ***.
Gene Symbol
ACAT2
DHCR7
EBP
FDFT1
FDPS
HMGCR

Gene Name
Fold Change Affymetrix ID
acetyl-CoA acetyltransferase 2
-1.29 *
209608_s_at
7-dehydrocholesterol reductase
-1.51 **
201790_s_at
emopamil binding protein (sterol isomerase)
-1.22 *
213787_s_at
farnesyl-diphosphate farnesyltransferase 1
-1.23 *
210950_s_at
farnesyl diphosphate synthase
-1.17 *
201275_at
3-hydroxy-3-methylglutaryl-CoA reductase
-1.42 ***
202539_s_at
3-hydroxy-3-methylglutaryl-CoA synthase 1
HMGCS1
-1.56 ***
221750_at
(soluble)
IDI1
isopentenyl-diphosphate delta isomerase 1
-1.92 ***
208881_x_at
lanosterol synthase (2,3-oxidosqualeneLSS
-1.29 *
202245_at
lanosterol cyclase)
MVD
mevalonate (diphospho) decarboxylase
-1.24 *
203027_s_at
sterol-C5-desaturase (ERG3 delta-5-desaturase
SC5DL
-1.26 *
211423_s_at
homolog, S. cerevisiae)-like
SQLE
squalene epoxidase
-1.37 **
209218_at
Table 2.2. List of genes which are significantly altered as a result of hPNPaseold-35
stable knockdown, and are associated with mitochondrial dysfunction, according to IPA
Toxicogenomic Analysis. FDR≤0.05 = *, FDR≤0.01 = **, FDR≤0.005 = ***.
Table 2A.

ETC components
Complex I

	
  

Gene
Gene name
symbol
NADH dehydrogenase (ubiquinone) 1 alpha
NDUFA2
subcomplex, 2, 8kDa
NADH dehydrogenase (ubiquinone) 1 alpha
NDUFA3
subcomplex, 3, 9kDa
NADH dehydrogenase (ubiquinone) 1 alpha
NDUFA8
subcomplex, 8, 19kDa
NDUFA1 NADH dehydrogenase (ubiquinone) 1 alpha
3
subcomplex, 13
NDUFAB NADH dehydrogenase (ubiquinone) 1,
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Fold
Affymetrix ID
change
-1.11 *
-1.32 ***
-1.14 *
1.22 **
-1.07 *

209224_s_at
218563_at
218160_at
220864_s_at
202077_at

	
  

Complex II

Complex III

Complex IV
Cytochrome c
oxidase
Complex V
ATP synthase

	
  

1
alpha/beta subcomplex, 1, 8kDa
NDUFAF NADH dehydrogenase (ubiquinone) complex
1
I, assembly factor 1
NADH dehydrogenase (ubiquinone) 1 beta
NDUFB4
subcomplex, 4, 15kDa
NADH dehydrogenase (ubiquinone) 1 beta
NDUFB5
subcomplex, 5, 16kDa
NADH dehydrogenase (ubiquinone) 1 beta
NDUFB7
subcomplex, 7, 18kDa
NADH dehydrogenase (ubiquinone) Fe-S
NDUFS1 protein 1, 75kDa (NADH-coenzyme Q
reductase)
NADH dehydrogenase (ubiquinone) Fe-S
NDUFS2 protein 2, 49kDa (NADH-coenzyme Q
reductase)
NADH dehydrogenase (ubiquinone) Fe-S
NDUFS3 protein 3, 30kDa (NADH-coenzyme Q
reductase)
succinate dehydrogenase complex, subunit
SDHB
B, iron sulfur (Ip)
succinate dehydrogenase complex, subunit
SDHC
C, integral membrane protein, 15kDa
ubiquinol-cytochrome c reductase, complex
UQCR10
III subunit X
ubiquinol-cytochrome c reductase, complex
UQCR11
III subunit XI
UQCRFS ubiquinol-cytochrome c reductase, Rieske
1
iron-sulfur polypeptide 1
cytochrome c oxidase subunit VIb
COX6B1
polypeptide 1 (ubiquitous)
cytochrome c oxidase subunit VIIa
COX7A1
polypeptide 1 (muscle)
SURF1 surfeit 1
ATP synthase, H+ transporting,
ATP5A1 mitochondrial F1 complex, alpha subunit 1,
cardiac muscle
ATP synthase, H+ transporting,
ATP5B
mitochondrial F1 complex, beta polypeptide
ATP5C1 ATP synthase, H+ transporting,
mitochondrial F1 complex, gamma
polypeptide 1
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-1.09 *
-1.09 *
-1.09 *
1.36 **

204125_at
218226_s_at
203621_at
202839_s_at

-1.22 ***
203039_s_at
-1.18 **
201966_at
-1.10 *
201740_at
-1.11 *
-1.19 *
-1.13 *
1.22 **
-1.32 ***
-1.31 ***

202675_at
210131_x_at
218190_s_at
202090_s_at
208909_at
201441_at

-1.80 ***

204570_at
-1.17 ** 204295_at
-1.12 **
213738_s_at
-1.10 *

201322_at

-1.40 *** 213366_x_at

	
  

Table 2B.
Mitochondria associated factors
Gene
Gene name
symbol
apoptosis-inducing factor, mitochondrionAIFM1
associated, 1
anterior pharynx defective 1 homolog B (C.
APH1B
elegans)
BACE2
beta-site APP-cleaving enzyme 2
CAT
catalase
CYB5R3
cytochrome b5 reductase 3
GLRX2
glutaredoxin 2
GPX4
glutathione peroxidase 4
GSR
glutathione reductase
HSD17B10 hydroxysteroid (17-beta) dehydrogenase 10
MAP2K4
mitogen-activated protein kinase kinase 4
PDHA1
pyruvate dehydrogenase (lipoamide) alpha 1
PSEN2
presenilin 2 (Alzheimer disease 4)
PSENEN
presenilin enhancer 2 homolog (C. elegans)
succinate dehydrogenase complex, subunit A,
SDHAP1
flavoprotein pseudogene 1
TRAK1
trafficking protein, kinesin binding 1
UCP2
uncoupling protein 2 (mitochondrial, proton carrier)
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Fold change Affymetrix ID
-1.11 ***
-1.37 **
-1.11 *
-1.45 ***
-1.10 *
-1.28 *
1.21 *
-1.31 *
-1.13 *
1.44 *
-1.15 *
-1.15 *
-1.26 *
-1.19 **
1.18 *
-3.22 ***

205512_s_at
221036_s_at
217867_x_at
201432_at
201885_s_at
219933_at
201106_at
205770_at
202282_at
203266_s_at
200980_s_at
211373_s_at
218302_at
222021_x_at
202080_s_at
208998_at

	
  

Fig. 2.6. qRT-PCR verification of two most significant
genes associated with (A) cholesterol biosynthesis and (B)
mitochondrial dysfunction in hPNPaseold-35 silenced HO-1
cells. Error bars represent mean ± S.E. of three replicate
experiments.
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2.4.3 Gene expression profile of Ad.hPNPaseold-35-infected melanoma cells
Overexpression of hPNPaseold-35 causes growth inhibition in a number of cancer
types and the growth prohibitive effects have been attributed to the downregulation of cmyc RNA by hPNPaseold-35. We performed a microarray analysis of HO-1 cells infected
with Ad.hPNPaseold-35 (Fig. 2.1.B) and compared the gene expression changes to cells
infected with Ad.vec to identify transcripts differentially regulated as a result of
hPNPaseold-35 overexpression. A total of 310 transcripts were upregulated and 407 were
downregulated significantly (FDR ≤ 0.05) (Fig. 2.2).
Significant gene expression changes associated with adenoviral overexpression
of hPNPaseold-35 could be classified into the following molecular and cellular functional
categories according to IPA (p-values ranging from 7.50E-16 – 2.05E-03): cell cycle,
cellular growth and proliferation, cell death and survival, DNA replication, recombination
and repair and cellular development (Fig. 2.7, Table S2A). Based on these functional
categories, 25 biological gene networks were generated by IPA with a score ranging
from 46 to 19 (Table S2D).
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Fig. 2.7. The biological functions and states associated with genes differentially
expressed when hPNPaseold-35 is overexpressed in human melanoma cells, as
identified by IPA.
	
  

The following are the most significant biological pathways altered when hPNPaseold-35
was overexpressed: hereditary breast cancer signaling, p53 signaling, cell cycle control
of chromosomal replication, IGF-1 and EIF2 signaling (Fig. 2.8, Table S2C).
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Fig. 2.8. Canonical pathways associated with genes differentially expressed when
hPNPaseold-35 is overexpressed in human melanoma cells.
	
  

In order to understand if these pathways were relevant to any disease phenotype, we
made use of the IPA-Tox analysis which identified p53 signaling, decreases in
Transmembrane Potential of Mitochondria and Mitochondrial Membrane (Table 2.3) and
Cell Cycle: G2/M DNA Damage Checkpoint Regulation (Table 2.4) as some of the
predicted significantly affected mechanisms (Fig. 2.9, Table S2B). The two main
pathways we were interested to analyze further were the ones involved with cell cycle
regulation and mitochondria, as there have been previous reports implicating a role for
hPNPaseold-35 in both of these cellular functions [47,93].
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Fig. 2.9. Toxicologically related functionalities and pathways associated with genes
dysregulated (proportions shown in graphs) after hPNPaseold-35 overexpression in
melanoma cells, as identified by IPA Toxicogenomic Analysis.
	
  

Overexpression of hPNPaseold-35 causes growth inhibition, which is partially attributed to
downregulation of c-myc [48], so it was not surprising to observe changes in gene
expression related to cell cycle regulation. Some of the most significantly altered genes
in this category were CCNB2, CDK1, CHEK2 and KAT2B. Another interesting
observation was the dysregulation of mitochondrial homeostasis, which again
emphasizes a role of hPNPaseold-35 in the mitochondria. These gene expression
changes could be due to a direct role that hPNPaseold-35 plays in the mitochondria or
affects associated with growth inhibition caused by hPNPaseold-35 overexpression. Some
of these significantly altered genes were FAS, BCL2L11 and BIRC5 (Table 2.3).
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Table 2.3. List of genes which are significantly altered as a result of hPNPaseold-35
overexpression, and are functionally associated with the maintenance of mitochondrial
transmembrane potential, according to IPA Toxicogenomic Analysis. FDR≤0.05 = *,
FDR≤0.01 = **, FDR≤0.005 = ***.
Gene Symbol
APAF1
BARD1
BCL2L11
BIRC5
BNIP3
CD47
CHEK2
CHMP5
FAS
IFI6
NFKB1
SLC25A14
SOD2
TGM2

	
  

Gene Name
apoptotic peptidase activating factor 1
BRCA1 associated RING domain 1
BCL2-like 11 (apoptosis facilitator)
baculoviral IAP repeat containing 5
BCL2/adenovirus E1B 19kDa interacting protein
3
CD47 molecule
checkpoint kinase 2
charged multivesicular body protein 5
Fas (TNF receptor superfamily, member 6)
interferon, alpha-inducible protein 6
nuclear factor of kappa light polypeptide gene
enhancer in B-cells 1
solute carrier family 25 (mitochondrial carrier,
brain), member 14
superoxide dismutase 2, mitochondrial
transglutaminase 2 (C polypeptide, proteinglutamine-gamma-glutamyltransferase)
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Fold Change
1.113**
-1.414**
1.351**
-1.312**

Affymetrix ID
211553_x_at
205345_at
222343_at
202094_at

-1.280**

201848_s_at

1.148**
-1.387**
1.715**
1.450**
1.345**

213857_s_at
210416_s_at
218085_at
204781_s_at
204415_at

-1.404**

209239_at

-1.155**

204587_at

1.384**

216841_s_at

1.423**

201042_at

	
  
Table 2.4. List of genes which are significantly altered as a result of hPNPaseold-35
overexpression, and are associated with G2/M DNA damage checkpoint regulation,
according to IPA Toxicogenomic Analysis. FDR≤0.05 = *, FDR≤0.01 = **, FDR≤0.005 =
***.
Gene Symbol Gene Name
BRCA1
breast cancer 1, early onset
CCNB2
cyclin B2
CDK1
cyclin-dependent kinase 1
CHEK2
checkpoint kinase 2
KAT2B
K(lysine) acetyltransferase 2B
SKP1/SKP1P2 S-phase kinase-associated protein 1
tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, beta
YWHAB
polypeptide
tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, zeta
YWHAZ
polypeptide

Fold Change
-1.235**
-1.217**
-1.496**
-1.387**
1.520**
1.173**

Affymetrix ID
211851_x_at
202705_at
203214_x_at
210416_s_at
203845_at
207974_s_at

-1.139**

217717_s_at

1.332**

200639_s_at

2.4.4 Identification of genes regulated by hPNPaseold-35
Bearing in mind that hPNPaseold-35 is functionally an exoribonuclease, there could
be two major mechanisms through which it could modulate gene expression; it could
either degrade target genes directly (“direct regulation”) or it could degrade miRNAs (or
mRNAs for other regulatory proteins) that in turn are regulators of certain genes
(“indirect regulation”). Since we had gene expression patterns corresponding to both
hPNPaseold-35 overexpression and knockdown, we employed stringent criteria to identify
genes that could be directly or indirectly regulated by hPNPaseold-35. Instead of making
the obvious choice of selecting genes that were inversely related to the expression of
hPNPaseold-35 in either microarray dataset, we performed an overlapping screen with the
help of the online tool VENNY [106] in order to identify transcripts whose expressions
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changed inversely in both the datasets. This comparison resulted in the identification of
77 potential hPNPaseold-35-directly regulated genes that were up-regulated when
hPNPaseold-35

was

depleted

and

down-regulated

when

hPNPaseold-35

was

overexpressed (Fig. 2.2.B; Table S3A, B). A second set of 61 transcripts that were
downregulated when hPNPaseold-35 was depleted by shRNA and up-regulated when
hPNPaseold-35 was overexpressed were also taken in consideration as potential
hPNPaseold-35-indirectly regulated genes (Fig. 2.2.C; Table S3C, D). All the genes in
these lists were significant with q-values ≤ 0.05.
In order to place the hPNPaseold-35-regulated genes into functional categories, we
made use of the ToppFun function of the ToppGene suite of web applications. A
summary of the GO categories with the maximum number of genes and the most
significant p-values is provided in Table 2.5.
Table 2.5. Functional and structural categories of genes associated with
hPNPaseold-35-driven regulation.
Functional category
“Directly” regulated genes
RNA binding
Chromosome organization
Cell cycle
Chromosome
Mitotic Prometaphase pathway
“Indirectly” regulated genes
Response to wounding
Vacuole
Integral to plasma membrane
CD molecules
miR-124a

	
  

Source

p-value

no. of genes

GO: Molecular Function
GO: Biological Process
GO: Biological Process
GO: Cellular Component
MSigDB

6.21E-05
1.28E-06
1.28E-06
1.46E-10
3.62E-02

13/894
19/751
25/1460
21/671
6/92

GO: Biological Process
GO: Cellular Component
GO: Cellular Component
Gene Family
(genenames.org)
MicroRNA (PicTar)

5.43E-03
4.74E-03
4.81E-02

16/1168
9/424
13/1328

3.45E-04
4.04E-02

5/276
11/626
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The hPNPaseold-35-directly regulated genes represent significant enrichment related to
RNA binding, chromosome organization and cell cycle associated (CENPE, MKI67,
POLD3, MCM4) functions (Table S4A). To determine how the hPNPaseold-35-regulated
genes might interact with each other, gene symbols were uploaded into GeneMANIA.
The directly-regulated genes form a densely correlated network with overlapping
functional categories akin to organelle fission, chromosome segregation and DNA
strand elongation as predicted by the gene functional analysis (Fig. 2.10). There was an
over-representation of genes related to cellular response to wounding (TGM2, SDC2,
MCAM), genes belonging to the CD family of cell surface receptors (DDR1, JAG1,
CD164, MCAM, CD47), and miR-124a predicted targets (SLC7A8, JAG1, SDC2,
CADM1, RNF128) in the hPNPaseold-35-indirectly regulated genes dataset (Table S4B).
These probe sets also form a network cluster comprised mainly of co-expressed genes
(Fig. 2.11). The inter-gene correlations between probe sets defined as being potentially
directly or indirectly regulated by hPNPaseold-35 were largely based on publically
available co-expression association data.
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Fig. 2.10. Network visualization of genes potentially “directly” regulated by
hPNPaseold-35.
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Fig. 2.11. Network visualization of genes potentially “indirectly” regulated by
hPNPaseold-35.
In	
   order to confirm select genes from the microarray analyses (microarray fold changes
provided in Table S3), five potential hPNPaseold-35-regulated genes were validated (for
the purpose of this study we validated only a few genes as it was not feasible to validate
all the hPNPaseold-35-regulated genes identified) by qRT-PCR to show their inverse
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correlation with hPNPaseold-35 expression in the HO-1 melanoma cell line as shown in
Figs. 2.12 and 2.13 (putative “direct target”: CENPE, MKI67; putative “indirect targets”:
VGF, RNF128). CENPE and MKI67 were chosen for validation as they were also
identified in an overlapping screen we performed between hPNPaseold-35-knockdown
cells and a doxycycline inducible hPNPaseold-35 overexpression system in HeLa cells
(Chapter 3) and showed a 20-40% increase upon hPNPaseold-35 knockdown and >40%
decrease following hPNPaseold-35 overexpression at the RNA level. VGF and RNF128
were chosen as they showed the maximum fold change in the hPNPaseold-35knockdown cells and showed >40-80% decrease by qRT-PCR following hPNPaseold-35
knockdown and ~20-50% increase following hPNPaseold-35 overexpression. Statistical
analysis determined using one-way analysis of variance followed by Dunnett’s multiple
comparison test in case of hPNPaseold-35 knockdown samples and by a two tailed
student’s t-test in case of hPNPaseold-35 overexpression samples, where *= P< 0.05, **=
P< 0.01 and ***=P< 0.001.
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Fig. 2.12. qRT-PCR verification of hPNPaseold-35-putative “directly” regulated genes
identified by microarray analyses in response to hPNPaseold-35 (A) knockdown or (B)
overexpression in HO-1 melanoma cells. Error bars represent mean ± S.E. error of
three replicate experiments.
	
  

	
  

59	
  

	
  

Fig. 2.13. qRT-PCR verification of hPNPaseold-35-putative “indirectly” regulated genes
identified by microarray analyses in response to hPNPaseold-35 (A) knockdown or (B)
overexpression in HO-1 melanoma cells. Error bars represent mean ± S.E. of three
replicate experiments.
	
  
Transient knockdown of hPNPaseold-35 using siRNA also showed the inverse correlation
of hPNPaseold-35 expression with potential direct targets CENPE, MKI67 (qRT-PCR
validation showed a ~20% increase in both) and indirect targets VGF, MCAM (qRT-PCR
validation showed a ~20% decrease in both) (Figure 2.14). Statistical analysis
determined using a two tailed student’s t-test, where *= P< 0.05, **= P< 0.01 and ***=P<
0.001.
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Fig. 2.14. (A) qRT-PCR expression of hPNPaseold-35 following transient transfection
with siRNA against hPNPaseold-35 normalized to scrambled control post 48 hour.
Immunoblot showing hPNPaseold-35 levels after siRNA transfection. (B) qRT-PCR
verification of hPNPaseold-35-putative (i) “directly” and (ii) “indirectly” regulated genes
after hPNPaseold-35 transient silencing post 48 h. Error bars represent mean ± S.E. of
two replicate experiments.
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The expression changes of four putative hPNPaseold-35-directly and indirectly regulated
genes were also validated using another melanoma cell line WM35 (Figs. 2.15-17).
MKI67 and CENPE showed a 1.2 and 1.5 fold increase at the RNA level following
hPNPaseold-35 knockdown respectively. Following hPNPaseold-35 overexpression in
WM35 cells, MKI67 and CENPE levels reduced 30 and 20% respectively. Both VGF
and MCAM RNA levels reduced 20% upon hPNPaseold-35 knockdown. Overexpression
of hPNPaseold-35 resulted in a 1.2 and 1.4 fold increases in MCAM and VGF RNA levels.
Statistical significance was determined using a two-tailed student’s t-test.
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Fig. 2.15. (A) Phase contrast LM (top) and GFP fluorescent micrographs (bottom) of
WM35 melanoma cells following transduction with GFP expressing scrambled
shRNA and hPNPaseold-35 shRNA1 expressing lentiviruses and selection with
puromycin. qRT-PCR expression of hPNPaseold-35 (hPNPaseold-35 knockdown)
normalized to control (shScramble). Mean values normalized to a GAPDH internal
reference; error bars represent mean ± S.E. of three replicate experiments. AntihPNPaseold-35 and EF1α loading control immunoblots. (B) qRT-PCR expression of
hPNPaseold-35 in WM35 cells infected with Ad.hPNPaseold-35 normalized to cells
infected with Ad.Vec for 36 hour. Immunoblot showing hPNPaseold-35 overexpression
compared to Ad.Vec post 36 hour of infection. Error bars represent mean ± S.E. of
three replicate experiments. * P < 0.02, ** P < 0.01.
	
  

Fig. 2.16. qRT-PCR verification of hPNPaseold-35-putative “directly” regulated genes
identified by microarray analyses in response to hPNPaseold-35 (A) knockdown or (B)
overexpression in WM35 melanoma cells. Error bars represent mean ± S.E. of two
replicate experiments done in triplicate.
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Fig. 2.17. qRT-PCR verification of hPNPaseold-35-putative “indirectly” regulated genes
identified by microarray analyses in response to hPNPaseold-35 (A) knockdown or (B)
overexpression in WM35 melanoma cells. Error bars represent mean ± S.E. of two
replicate experiments done in triplicate.	
  

Finally, some of the hPNPaseold-35 direct and indirect targets were validated by qRTPCR in two additional melanoma cell lines (C8161 and MeWo) following transient
knockdown of hPNPaseold-35 in order to show that the decrease or increase in transcript
levels was not due to indirect effects of stable knockdown. Direct target CENPE showed
a ~1.2 fold increase in C8161 and MeWo cells both; MKI67 showed a 1.2 fold increase
in C8161 cells at the RNA level. Levels of indirect targets MCAM and RNF128
decreased 40 and 50% in C8161 cells and 10 and 20% in MeWo melanoma cells.
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Fig. 2.18. qRT-PCR expression of hPNPaseold-35 following transient
transfection with siRNA against hPNPaseold-35 normalized to scrambled
control post 48 h in C8161 (A) and MeWo (B) melanoma cells. Error bars
represent mean ± S.E. of two replicate experiments. Statistical significance
determined using two-tailed student’s t-test, *P<0.05, **P<0.01, ***P<0.001. 	
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2.4.5 hPNPaseold-35 stable knockdown in melanoma cells and invasion
Analysis of the microarray results following hPNPaseold-35 stable knockdown in
HO-1 melanoma cells revealed gene expression changes in numerous genes
associated with cellular invasion. Thus we decided to analyze any effect that stable
knockdown of hPNPaseold-35 may have on cellular invasion using matrigel based Boyden
chambers. We observed that stable knockdown of hPNPaseold-35 in HO-1 melanoma
cells resulted in a ~2-3 fold increase in in vitro invasion in two hPNPaseold-35 knockdown
clones we tested (Figure 2.19A). Next we checked the relative mRNA levels of a few of
the genes that maybe related to cellular invasion based on our knowledge of current
literature. We observed a ~6-10 fold increase in the levels of EMR1 (egf-like module
containing, mucin-like, hormone receptor-like 1; a gene that was the most upregulated
(3 fold) transcript in our hPNPaseold-35 knockdown microarray results), a ~2 fold increase
in MMP2 (matrix metallopeptidase 2) , FN1 (fibronectin 1) and CADM3 (cell adhesion
molecule 3) (Figure 2.19B). MMP2 and FN1 are well-studied proteins that have been
known to be involved in the invasion-related functions of numerous cancer cell types,
and currently we believe that the slight increase we observe in their levels could be an
indirect effect (could be miRNA related) of hPNPaseold-35 knockdown rather than a direct
effect mediated by hPNPaseold-35 degradation of these transcripts. On the other hand,
there are no known reports relating EMR1 or CADM3 to invasion, but we were
interested to pursue them, as they are cell surface receptors and could potentially play a
role in cell-cell signaling events. There are some studies where the homologues of
EMR1, EMR2 and 3, have been associated with poor prognosis and an invasive
phenotype in glioblastoma. Thus we decided to check EMR1 levels in another
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melanoma cell line, WM35 following stable hPNPaseold-35 knockdown, but we did not
observe an increase in its levels, instead we observed a decrease (Figure 2.20). Thus
at the current moment we believe that EMR1 is probably an indirect target of
hPNPaseold-35 whose levels may probably be regulated by certain miRNA species and
the modest increase in invasion we observe following hPNPaseold-35 knockdown in HO-1
melanoma cells may be attributed to the cumulative upregulation of cellular invasion
related genes like EMR1, MMP2, FN1. Future studies in additional melanoma cell lines
would be required and levels of other invasion related genes (levels of other EMR1
homologues like EMR2 and 3 may also be checked) or miRNAs would need to be
determined in order to evaluate the mechanism behind the increase in cellular invasion
observed following stable hPNPaseold-35 knockdown.
Since we saw an increase in EMR1 levels upon hPNPaseold-35 knockdown at
least in HO-1 melanoma cells, we were still interested to pursue this molecule further
and see if there was any correlation between EMR1 and hPNPaseold-35 levels in tumor
versus normal tissue samples to analyze if there was any potential biological
significance of this hypothesized indirect effect of hPNPaseold-35 knockdown on EMR1
levels. In order to do this we purchased multiple melanoma tissue array slides with
tissue

sections

from

normal

and

different

tumor

stages

and

performed

immunohistochemistry (IHC) with hPNPaseold-35 and EMR1 specific antibodies. Visual
observation of the stained IHC slides showed that EMR1 levels seem to increase and
hPNPaseold-35 levels decrease with tumor stage (Stage II-IV) (Figure 2.21). Also the
adjacent normal tissue sections seem to have higher levels of hPNPaseold-35 and lower
levels of EMR1 compared to their tumor counterparts. From this preliminary result we
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can conclude that there seems to be an inverse correlation between hPNPaseold-35 and
EMR1 levels, which may or may not be due to hPNPaseold-35 direct or indirect regulation.
Future studies would be required to further explore this premise and as suggested
earlier, identification of hPNPaseold-35 –degradable miRNA species regulating EMR1
may allow recognition of therapeutic opportunities for cancers with high levels of EMR1.
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old-35

Fig. 2.19. hPNPase
knockdown and invasion of HO-1 melanoma cells (A)
Invasion assay images and graphical representation of invasion assay results of scrambled
shRNA control and hPNPaseold-35 shRNA stably transduced HO-1 melanoma cells. Error bars
represent mean ± standard error of two independent experiments done in duplicate. (B) qRTPCR validation of invasion related genes identified in microarray results. Error bars represent
mean ± standard error of three independent experiments done in triplicate. Statistical
significance was determined using a one-way analysis of variance followed by Dunnett’s
multiple comparison test. *P<0.05, **P<0.01, ***P<0.001. 	
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Fig. 2.20. qRT-PCR validation of hPNPaseold-35 and EMR1 levels in WM35
melanoma cells following stable hPNPaseold-35 knockdown. Error bars represent
mean ± standard error of two independent experiments done in triplicate. **P<0.01.	
  

Fig. 2.21. Representative images of immunohistochemistry analysis of multiple
malignant melanoma tissue arrays.	
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2.5 Discussion
Numerous studies performed over the past decade have utilized the RNAi
methodology to evaluate the functions of hPNPaseold-35. Most of these studies
concentrated on studying the role of hPNPaseold-35 in reference to its mitochondrial
location with special emphasis on mtRNA processing, maintenance of mitochondrial
homeostasis

and

more

recently

its

role

in

mitochondrial

RNA

import

[44,47,50,51,76,87]. In other studies, overexpression of hPNPaseold-35 has been shown
to cause growth inhibition attributed to downregulation of c-myc and miR-221 by its
exoribonuclease activity in the cytosol [48,49]. In this study we have incorporated both
these classic genetic approaches of gene knockdown and overexpression to further
understand hPNPaseold-35 functions on a more comprehensive level. This is the first
attempt of its kind aimed at studying global gene expression changes resulting from
hPNPaseold-35 knockdown or overexpression in order to identify unique genes regulated
by hPNPaseold-35. In this manuscript we focus on the analysis of gene expression
patterns of the most relevant biological pathways of hPNPaseold-35 potential functions.
Our results show that stable knockdown of hPNPaseold-35 in melanoma cells
affects mitochondrial function and cholesterol biosynthesis. Other groups have
previously reported the importance of hPNPaseold-35 in the maintenance of mitochondrial
homeostasis through knockdown and liver specific knockout experiments where they
showed a deregulation of the various respiratory complexes in the Electron Transport
Chain (ETC) following hPNPaseold-35 silencing [44,47]. These results further strengthen
those findings. In this study we report novel genes (Table 2.2) that encode for proteins
constituting the various ETC respiratory complexes, which were differentially expressed
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in our hPNPaseold-35 knockdown melanoma cells. Some mitochondrial accessory factors
were also affected and one of them UCP2 [107], which is a mitochondrial anion
transporter that plays a role in energy dissipation and maintenance of mitochondrial
membrane potential was downregulated ~3-fold (Fig. 2.6.B). The exact mechanism of
how hPNPaseold-35 regulates these genes remains to be elucidated and the possibilities
may be numerous ranging from RNA degradation, miRNA regulation or RNA import.
Moreover, recently mutations in hPNPaseold-35 have also been identified that impair
respiratory-chain activity [108]. The ETC genes identified in this study identify the
specific genes affected by hPNPaseold-35 that maybe causative for mitochondrial
dysfunction. Further studies aimed at understanding the functional implications of the
identified genes may provide valuable insight to the physiological role of hPNPaseold-35
in mitochondrial diseases and discovering suitable therapeutic options.
We also identified genes belonging to the cholesterol biosynthesis pathway that
were significantly downregulated with depletion of hPNPaseold-35. This is a novel and
potentially biologically important result since association of hPNPaseold-35 with this
pathway has not been previously reported. Mitochondrial dynamics have been linked to
steroid biosynthesis and the gene expression changes we observed pertaining to
cholesterol biosynthesis could be a consequence of mitochondrial dysfunction, or vice
versa. Additionally, since this analysis was performed in a stable cell line in which
hPNPaseold-35 was silenced, certain compensatory changes could be acquired over time
as opposed to primary effects of gene knockdown. On the other hand hPNPaseold-35
could indeed directly regulate the RNA levels of these genes or alter their expression by
regulating upstream transcriptional control elements. SREBF2 is one such transcription
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factor that was found to be downregulated 1.3-fold in our microarray analyses which
regulates the expression of HMGCR (Fig. 2.6.A), HMGCS1 and IDI1. Further studies to
address and evaluate these possibilities would be required to assess the relevance of
hPNPaseold-35 in this context.
Previous studies have shown that adenoviral overexpression of hPNPaseold-35
induces growth suppression and a senescence-like phenotype [17,48]. Our present
analyses show that the majority of genes differentially expressed as a result of
adenoviral overexpression of hPNPaseold-35 compared to the empty vector control
(Ad.Vec) belong to cell cycle, cellular assembly and organization categories. Biological
pathways likely affected as a consequence of the gene expression changes included
cell cycle control of chromosomal replication. Key genes down-regulated more than 1.5fold in this category belonged to the mini-chromosome maintenance complex (MCM2,
MCM4-7) that is essential for eukaryotic DNA replication. Important regulators of G2/M
DNA damage checkpoint control; CCNB2, CHEK2 and CDK1 were also downregulated.
The gene expression changes of these cell-cycle regulators may contribute towards
tipping the balance in the cell in the direction of growth inhibition. Also, changes in gene
expression were identified in apoptosis regulatory molecules. FAS, BIK and BCL2L11
(pro-apoptotic) expression was increased and BIRC5 (anti-apoptotic) levels were
reduced significantly, which may have played a role in decreasing the transmembrane
potential of the mitochondrial membrane observed upon hPNPaseold-35 overexpression
in the IPA analyses, an important phenomenon implicated in apoptosis [109]. These
findings provide new information regarding the cell-cycle associated implications of
hPNPaseold-35 overexpression and provide targets for further studies. These findings are
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also supported by previous studies; where it was shown that terminal differentiation
(which shares overlapping characteristics with cellular senescence) of HO-1 melanoma
cells caused by combination treatment with IFN-β plus the protein kinase C activator
mezerein resulted in global gene expression reductions of cell-cycle associated genes
[110,111]. hPNPaseold-35 is a Type I-IFN inducible early response gene [42]; thus it was
not surprising that we observed a similar pattern of gene expression changes in our
present study involving hPNPaseold-35 overexpression. The candidate genes identified
may also provide insight regarding the role of hPNPaseold-35 in aging-associated
inflammation [74,79]. Some of the potentially biologically significant genes in this
category were CAPN3, BIRC5, TRIM2, CENPF, FN1, BCL6 and GMNN. This premise
needs further attention, as it is evident that the cell-cycle changes associated with
hPNPaseold-35 overexpression are diverse and complex. Also, c-myc is a key regulator of
cell-cycle progression, which is targeted by hPNPaseold-35 for degradation. Bearing this
in mind, in the present study we chose an earlier time point of 36 hours, before changes
in the c-myc transcript levels were evident, to study Ad.hPNPaseold-35 associated gene
expression changes. Even so, in order to identify genes directly targeted by hPNPaseold35

irrespective of c-myc status we plan to study the effects of hPNPaseold-35

overexpression in a c-myc null background [112,113].
To identify additional genes regulated by hPNPaseold-35, we ascertained
transcripts in our two separate datasets (i.e. hPNPaseold-35 knockdown and
overexpression) whose expression inversely correlated with hPNPaseold-35. This novel
strategy helped us detect 77 potential “directly” (mRNA degraded by hPNPaseold-35) and
61 potential “indirectly” (miRNAs targeting these transcripts degraded by hPNPaseold-35)
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regulated transcripts. Although in this study we have concentrated on this small list of
genes identified through the overlapping approach between our hPNPaseold-35 depleted
and overexpression datasets, future studies would be required to analyze the remaining
genes whose expression is also regulated by hPNPaseold-35 but do not fall in this list
(Figs. 2.2.B-C). Most of these potential “direct” targets were genes implicated in cellcycle associated functions and two of them have been validated by qRT-PCR; CENPE
(Centromere protein E) which is involved in mitotic checkpoint control [114,115] and
MKI67 (antigen identified by monoclonal antibody Ki-67), a known cellular proliferation
marker implicated in rRNA synthesis [116-118]. Since most of the genes thought to be
“directly” regulated belong to a closely associated network of cell cycle regulatory
functions, at this point it is difficult to say whether these gene expression changes
represent global effects of hPNPaseold-35 deregulation caused by key upstream
regulators or if they are genes that are directly targeted by hPNPaseold-35 for
degradation. Future studies using in vitro mRNA degradation assays will help answer
these questions. Among the “indirectly” regulated targets, a fraction of genes were
identified that had conserved sites for miR-124a (Table S4). We validated one of these
genes by qRT-PCR; RNF128 (ring finger protein 128) an E3 ubiquitin ligase that is
involved in the regulation of cytokine gene transcription [119]. Another potential indirect
target we validated was VGF (VGF nerve growth factor inducible), which encodes a
neuro-endocrine polypeptide implicated in a vast array of biological phenomena that
include energy metabolism and inflammation [120-122]. Identification and subsequent
validation of miRNAs targeting the genes we identified would aid in clarifying the role of
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hPNPaseold-35, if any, in the context of the relevant biological processes these genes are
implicated in and would further allow appropriate therapeutic intervention.
In summation, this study has produced a novel genetic and genomic analysis of
the functional implications for alterations in PNPT1 gene expression. Our analysis has
identified a limited set of candidate genes for direct regulation by hPNPaseold-35. Such
genes could provide novel targets for intervention in hPNPaseold-35-related disease
states. Furthermore, this work has generated a comprehensive database of hPNPaseold35

-responsive genes that are potentially relevant to the mechanisms of global cellular

functions affected by this important regulatory molecule.
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CHAPTER THREE

Analysis of global changes in gene expression induced by human polynucleotide
phosphorylase (hPNPaseold-35)
3.1 Abstract
In an attempt to identify gene expression changes induced by human
polynucleotide phosphorylase (hPNPaseold-35) we performed genes expression analysis
of HeLa cells in which hPNPaseold-35 was overexpressed and compared these changes
to HO-1 melanoma cells in which stably knocked down hPNPaseold-35. We identified 90
transcripts following this analysis which positively or negatively correlated with hPNPase
expression and most of which were associated with cell communication, cell cycle and
chromosomal organization gene ontology categories. Some of these genes were also
identified in four TCGA (The Cancer Genome Atlas) datasets we screened, colon
adenocarcinoma (COAD), skin cutaneous melanoma (SKCM), ovarian serous cyst
adenocarcinoma (OV), and prostate adenocarcinoma (PRAD), with expressions
correlating with hPNPaseold-35 as we identified in our microarray analysis. Further
analysis comparing the gene expression changes between Ad.hPNPaseold-35 infected
HO-1 melanoma cells and HeLa cells overexpressing hPNPaseold-35 under the control of
a doxycycline-inducble promoter, revealed global changes in genes involved in cell
cycle and mitosis. This study provides further evidence that hPNPaseold-35 is associated
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with global changes in cell cycle-associated genes.
3.2 Introduction
Human

polynucleotide

phosphorylase,

an

evolutionarily

conserved

3’-5’

exoribonuclease, has been implicated in numerous cellular functions over the past
decade since its discovery as an upregulated transcript in terminally differentiated
melanoma cells and senescent fibroblasts [17]. Some of the major findings relating to
this interesting enzymatic protein revolve around its ability to cause growth suppression
of cancer cells as a result of c-myc mRNA degradation and more recently due to its
post-transcriptional regulation of miR-221 [48,49]. It is also implicated in the generation
of reactive oxygen species leading to chronic inflammation, suggesting a probable role
for this enzyme in senescence associated degenerative diseases [74,75]. Apart from
this hPNPaseold-35 plays a major role in the maintenance of cellular homeostasis,
imports RNA into the mitochondria, mediates mtRNA processing and is part of a
complex that is responsible for mtRNA decay [44,47,50,76,87,88]. Although these
findings are a major step forward in delineating the functional roles this enzyme plays in
cellular physiology, not a lot is known about the molecular targets of hPNPaseold-35 from
an enzymatic perspective apart from c-myc and miR-221 and its processing activities in
the mitochondria.
Thus, to further our quest in trying to unravel the molecular targets involved in the
biological processes hPNPaseold-35 regulates which would ultimately help in the
identification of therapeutic targets, we decided to perform gene expression analysis of
melanoma cell lines following gain or loss of function of hPNPaseold-35. Pertaining to this,
we provide extensive details in Chapter 2, where we have attempted to unravel the
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global implications of hPNPaseold-35 deregulation using melanoma as a model system.
We have been able to identify transcripts that may be direct or indirect targets of
hPNPaseold-35, while also showing and reinforcing the fact that hPNPaseold-35 regulates
mitochondrial homeostasis and cell cycle associated pathways.
As an extension of Chapter 2 we wanted to explore the possibility of whether
similar effects would be observed in a system other than melanoma. In order to do this
we performed microarray analysis in HeLa cells to evaluate the gene expression
changes occurring as a result of hPNPaseold-35 overexpression, which would help us
answer whether the changes we observed in the HO-1 cells were a more global
phenomana or a cell type specific effect. Also, to attain overexpression levels of
hPNPaseold-35 that were more physiologically relevant we made use of a doxycyclineinducible overexpression system. To identify hPNPaseold-35 induced or repressed genes,
we overlapped these microarray results with the hPNPaseold-35 knockdown data we
reported in Chapter 2. Secondly, we explored the TCGA database to identify in vivo
tissue correlations of the genes we identified with hPNPaseold-35 expression levels which
provides additional validation for our current findings. Finally, we also compared the
gene expression changes occurring as a result of hPNPaseold-35 overexpression in HeLa
cells and the Ad.hPNPaseold-35 infected HO-1 cells we described in Chapter 2 to
understand the global implications of hPNPaseold-35 upregulation. This study provides
further proof of the global impact of hPNPaseold-35 on cell cycle events and the identified
targets provide us with additional information, which may be used for the recognition of
possible therapeutic targets for hPNPaseold-35 associated diseases.
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3.3 Materials and methods
3.3.1 Establishing a conditional hPNPaseold-35old-35 over-expressing cell line
The full-length cDNA of hPNPaseold-35old-35 with a C-terminal HA tag was cloned
into a modified version of the Tet-On pTRIPZ vector (Open Biosystems, provided by Dr.
Kristoffer Valerie) to permit inducible expression of the gene in the presence of
doxycycline. HeLa-Tet-On cell lines were established by transfecting HeLa cells
(Lipofectamine 2000, Invitrogen) with the pTRIPZ -hPNPaseold-35old-35 plasmid (sequence
was verified before use) and stable clones were selected with the help of puromycin (2
µg/ml) supplemented media. The expression of hPNPaseold-35old-35 in the different clones
was tested after inducing with doxycycline by Western blotting analysis.
3.3.2 MTT and colony formation assays
Dox-inducible HeLa cell clones 5, 6, 7 and 27 were seeded in 96-well plates (in
quadruplicates) at a density of 1000 cells per well and difference in cellular viability
between the dox-induced and uninduced controls was monitored by 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) staining over a period of 5
days. The same cells were also seeded in 6-cm plates at a density of 1000 cells per
plate and doxycycline was added. Colonies in the dox-treated and untreated plates
(done in triplicates) were counted after 2 weeks by treating with Giemsa stain. Normal
HeLa cells and pTRIPZ-RFP HeLa cells (with and without dox) were used as additional
controls in both of the above experiments.
3.3.3 Total RNA isolation for microarray analyses
Total RNA from the hPNPaseold-35old-35 knockdown and control cell lines (HO-1
melanoma cells stably expressing shRNA for hPNPaseold-35old-35 and scrambled control
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shRNA) and the hPNPaseold-35old-35 conditionally over-expressing doxycycline treated
and untreated control cell lines (HeLa cells stably transfected with pTRIPZ-hPNPaseold35old-35

induced with doxycycline for 24 hrs and uninduced cells as control) was isolated

from cell lysates in TRIZOL reagent (InvitrogenTM Life Technologies, Carlsbad, CA).
Cell lysates were subjected to an automated extraction method using the MagMAX™96 for Microarrays Total RNA Isolation Kit (Ambion/InvitrogenTM Life Technologies,
Carlsbad, CA) on the MagMAX™ Express Magnetic Particle Processor (Applied
Biosystems/InvitrogenTM LifeTechnologies, Carlsbad, CA).
3.3.4 Gene Expression Microarrays
Gene expression profiles were ascertained using GeneChip® Human Genome
U133A 2.0 (HG-U133A 2.0) arrays (Affymetrix, Santa Clara, CA) as previously
described [100]. Every chip was scanned at a high resolution, with pixelations ranging
from 2.5 µm down to 0.51 µm, by the Affymetrix GeneChip® Scanner 3000 according to
the GeneChip® Expression Analysis Technical Manual procedures (Affymetrix, Santa
Clara, CA). After scanning, the raw intensities for every probe were stored in electronic
files (in .DAT and .CEL formats) by the GeneChip® Operating Software (GCOS)
(Affymetrix, Santa Clara, CA). The overall quality of each array was assessed by
monitoring the 3′/5′ ratios for a housekeeping gene (GAPDH) and the percentage of
“Present” genes (%P); where arrays exhibiting GAPDH 3′/5′ < 3.0 and %P > 40% were
considered good quality arrays. All experiments were done in biological triplicates.
3.3.5 Statistical Analyses
The Robust Multiarray Average method (RMA) was used for normalization and
obtaining probe set expression summaries for the gene expression assays. These
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values were then used to identify genes significantly altered among the different
conditions (i.e., hPNPaseold-35old-35 up- and down-regulation), and analyzed for
significance across replicate experiments with the help of TM4-MeV (MultiExperiment
Viewer) analysis software by using a permutation method performed with the
Significance Analysis of Microarray (SAM) program from Stanford University [Stanford,
CA]. Once the program reported the list of ranked genes whose expression changed in
the opposite direction in the two datasets, the “delta value” was adjusted to a stringent
false discovery rate (FDR) of 5%. Cluster analysis was done using the Cluster and
TreeView programs 4. Genes reported by SAM were analyzed by hierarchical clustering
with average linkage grouping.
In order to identify transcripts whose expression negatively or positively
correlated with the expression of c-myc, we employed a Pearson correlation coefficient
of 0.01 and statistical significance of the identified genes was set at p-value cutoff of
0.05 using standard t-test.
3.3.6 Enrichment analysis
The Protein ANalysis THrough Evolutionary Relationships (PANTHER) resource
was used to identify Gene Ontology (GO) categories and generate pie charts for the
hPNPaseold-35 responsive genes (www.pantherdb.org) [123-125]. PANTHER can
categorize genes based on their molecular functions, biological processes and protein
classes with the help of available literature and evolutionary relationships.
Functional annotation cluster analysis was done using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) for the Gene ontology-based functional
enrichment of the gene lists, using their respective gene symbols [126-128]. This kind of
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analysis allows us to group functionally related genes together, which in turn provides a
global view of altered biological networks.
The MetaCore™ (GeneGo Inc. USA) bioinformatics software was used in order
to gain a deeper understanding of the plausible molecular networks or biological
pathways the hPNPaseold-35 responsive might be involved in [129,130]. The build
network tool assigns pathway significance based upon the number of genes
represented within a pathway and the direction of change.
The comparison analysis tool in the IPA (Ingenuity Pathway Analysis) software
was used to evaluate the common biological processes and canonical pathways
between the doxycycline-inducible HeLa hPNPaseold-35 overexpression system and the
Ad.hPNPaseold-35 infected HO-1 cells.
3.3.7 Analysis of TCGA Genome-wide Expression Datasets
The processed, Illumina Hi Seq 2000-generated TCGA (The Cancer Genome
Atlas) genome-wide expression datasets for colon adenocarcinoma (COAD), skin
cutaneous melanoma (SKCM), OV (ovarian serous cystadenocarcinoma) and PRAD
(prostate adenocarcinoma) were obtained through the UCSC Cancer Genomics
Browser (https://genome-cancer.ucsc.edu/) (Goldman M et al, 2013).

The sample

breakdown for each dataset is as follows: COAD (193 primary, tumors, 18 solid tissue
normal), SKCM (241 metastatic, samples, 43 primary tumors), OV (262 primary tumors,
4 recurrent tumors), PRAD (176 primary tumors, 44 solid tissue normals). In addition,
the UCSC pan cancer (PANCAN) dataset (Cline MS et al., 2013), which resulted from
merging (and normalization) of all of the 22 TCGA genome wide expression (Illumina Hi
Seq 2000) cancer cohorts (including COAD, OV, PRAD, and SKCM) with a combined
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total of 6040 samples (4982 primary tumors, 271 metastatic, 27 recurrent tumors, 173
peripheral blood, 587 solid tissue normals), was downloaded from the same website
and subsequently analyzed. The primary objective of the analyses was to examine the
possible transcriptional correlations between hPNPase (PNPT1) and genes identified
through the cell line-based experiments. Through the use of the Gene-E program
(Broad Institute, Cambridge, MA) and the JMP 10 Pro statistical software (SAS, Cary,
NC), the correlations between hPNPase expression levels and those of other genes of
interest were examined by calculation of Pearson correlation coefficients and generation
of heat maps.
3.3.8 cDNA synthesis and quantitative real-time RT-PCR (qRT-PCR)
Total RNA was harvested using the RNeasy purification kit (Qiagen). The quality
and concentrations of isolated RNA samples were assessed using the NanoDrop 2000
(Thermo Scientific). 2 µg of RNA was used in a total volume of 20 µl to synthesize
cDNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems)
according to the manufacturer’s instructions. Real-time quantitative PCR was conducted
using the ViiATM 7 Real-Time PCR System (Applied Biosystems) and performed in a
total volume of 20 µl that contained the TaqMan Gene Expression Master Mix (Applied
Biosystems), 1 µl of the cDNA template generated and the target-specific TaqMan Gene
expression assays (Applied Biosystems) according to following cycle parameters: 95°C
for 10 minutes followed by 40 cycles at 95°C for 15 seconds and at 60°C for 1 minute.
Each sample was run in triplicate using three biological replicates and normalized to the
housekeeping gene GAPDH used as an internal control in each case. The ΔΔCt method
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was used for comparing relative fold expression differences in the genes of interest
between different test samples.
3.3.9 Protein isolation and Western blot analysis
Cells were harvested by centrifugation, pellets washed in PBS and subsequently
lysed in ice-cold 1X cell lysis buffer (Cell Signaling) supplemented with PhosSTOP
Phosphatase Inhibitor Cocktail Tablets and complete Mini Protease Inhibitor Cocktail
Tablets (Roche), followed by centrifugation at 13,000 rpm for 15 minutes at 4°C. The
supernatant or whole cell lysate was collected in a fresh tube and protein concentration
was measured using the Bio-Rad Protein Assay Dye Reagent Concentrate (BIO-RAD).
30 µg of total cell lysate was mixed with SDS sample buffer and heated for 5 minutes at
95°C. The proteins were separated by 8-10% SDS-PAGE gels and transferred onto
nitrocellulose membranes and blocked using 5% non-fat milk supplemented with 1%
bovine serum albumin (BSA) in TBS-T for 1 hour. After washing three times with TBS-T
for 10 minutes each, the membranes were incubated with primary antibodies overnight
at 4°C. The primary antibodies used were anti-HA (mouse, 1:1000), anti-hPNPaseold35old-35

(chicken; 1:5000), anti-EF1α (mouse, 1:1000). The next day membranes were

washed as before and incubated with the relevant horseradish-peroxidase conjugated
secondary antibodies for 1 hour at room temperature. After washing three times with
TBS-T for 10 minutes each, the proteins were detected using ECL Western Blotting
detection reagent (GE Healthcare Life Sciences) and exposed to X-ray film.
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3.4 Results
3.4.1 Establishing a doxycycline-inducible hPNPaseold-35 over-expression system
The stable clones selected were evaluated for hPNPaseold-35 expression by
Western blotting. Figure 3.1 represents the results obtained for clones 5, 6, 7 and 27,
where protein expression was checked at different time points and with increasing
doses of doxycycline separately. Clone 5 showed better responses to different doses
and temporal expression than the other clones and was thus selected for microarray
analysis.
Previous studies have established a role for hPNPaseold-35 in the processes of
growth inhibition, where it was overexpressed by means of a replication-deficient
adenovirus. In order to corroborate these results in the present overexpression system,
MTT cell viability assays and colony formation assays were performed. Doxycycline
treated clones 5 and 6 showed a slower growth rate (~40% less) as compared to their
untreated counterparts as measured by MTT reagent (Figure 3.2) and reduced number
of colonies (~50% less colonies) (Figure 3.3), when hPNPaseold-35 was overexpressed
as compared to clones 7 and 27 (Figures 3.3 and 3.4). The control HeLa cells and the
empty pTRIPZ vector HeLa clones did not show any significant difference in growth with
or without the presence of doxycycline (Figure 3.4).
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Fig. 3.1. Western blots showing hPNPase

overexpression in doxycyclineinducible stable HeLa cells in a time and dose-dependent manner.	
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Fig. 3.2. MTT cell viability assays. hPNPaseold-35 overexpression in doxycyclineinducible stable HeLa clones (A-D) shows a reduction in cellular growth over a period
of 5 days as determined by MTT assay. Error bars represent mean ± standard error
of one experiment done in quintuplicate, statistical significance determined by twotailed student’s t-test, *P<0.05.	
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Fig. 3.3. Colony formation assays. hPNPaseold-35 overexpression in doxycycline-inducible
stable HeLa clones (A-D) shows a reduction in cellular growth as observed by reduced
number of stained colonies. 	
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Fig. 3.4. Colony formation and MTT assays to determine cell viability of control HeLa
and HeLa-RFP cells. Error bars represent mean ± standard error of one experiment done in
quintuplicate.	
  
	
  

3.4.2 Identification of hPNPaseold-35 responsive genes
To explore the effects of hPNPaseold-35 on the global regulation of gene
expression, we conducted cDNA microarray analyses using HeLa cells stably
transfected with a doxycycline-inducible hPNPaseold-35 expression vector to attain
physiologically relevant levels of hPNPaseold-35 overexpression and HO-1 melanoma
cells in which hPNPaseold-35 expression was stably knocked down using shRNA
(described in detail in Chapter 2). Unsupervised hierarchical cluster analyses revealed
that the six HeLa and six HO-1 arrays cluster with their respective class (Figure 3.5),
which implies that the microarray results are robust and can differentiate between the
cell types.
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Fig. 3.5. Unsupervised hierarchical cluster analysis.
Unsupervised cluster dendrogram using centered
correlation and average linkage, based on 22,227 probe
sets for the 12-array dataset.	
  

A comparative analysis between the two datasets with the help of TM4-MeV
analysis software allowed the identification of 90 transcripts whose expression was
inversely affected in both datasets significantly. Out of these 90 transcripts, the
expression of 62 transcripts correlated positively with hPNPaseold-35 (Figure 3.6.A) and
the expression of 28 transcripts anti-correlated or negatively correlated with hPNPaseold35

(Figure 3.6.B). Some genes are represented on the microarray by multiple probe sets

and thus were identified more than once (as evident in Figure 3.6). Apart from providing
an additional internal control, this finding also increases confidence in the identification
of certain genes as being responsive to hPNPaseold-35 levels.
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Fig. 3.6. Comparison of hPNPaseold-35-induced changes in gene expression in
HO-1 and HeLa cells. Hierarchical clustering of hPNPaseold-35 positively (A) and
negatively (B) correlating genes as identified by microarray analysis.
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3.4.3 Functional categorization of hPNPaseold-35 responsive genes
The hPNPaseold-35 responsive genes were arranged into various biological
processes, molecular functions and protein classes using the Gene Ontology (GO)
categories available through the PANTHER database and its tools. These functional
categories are represented in Figure 3.7 where the pie charts include categories with at
least five genes. GO analysis of the biological processes (12 identified in total) involving
the hPNPaseold-35 responsive genes we report here showed that the major categories in
this case belonged to cellular (18.5%) and metabolic processes (17.6%). The genes
involved in cellular processes belonged majorly to cell communication (36.4%), cell
cycle (19.5%) and cell adhesion (16.9%) sub-categories.

Fig. 3.7. Gene Ontology (GO) terms for PNPase responsive genes. GO
analysis corresponding to Biological process	
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The genes involved with metabolic processes belonged majorly to primary
metabolic processes (86%), which in turn comprised of nucleic acid (38.3%), protein
(34%), lipid (14.9%), amino acid (8.5%) and carbohydrate metabolism (4.3%). The
major molecular functions the hPNPaseold-35 responsive genes were attributed to were
catalytic activity (29.2%, mainly hydrolases, oxidoreductases and transferases) and
binding (28.3%, mainly protein and nucleic acid binding) (Figure 3.8).

Fig. 3.8. Gene Ontology (GO) terms for PNPase responsive genes. GO analysis
corresponding to Molecular functions. 	
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The top protein function categories the hPNPaseold-35 responsive genes belonged
to were; hydrolases (12.4%), nucleic acid binding (10%) and receptors (8.5%) (Figure
3.9).

Fig. 3.9. Gene Ontology (GO) terms for PNPase responsive genes corresponding to
PANTHER Protein class identified by PANTHER classification system
(http://www.pantherdb.org/).	
  
Functional annotation clustering by DAVID resulted in the identification of 32 clusters of
related genes, with the highest enrichment score being 1.91. The most significantly
enriched gene clusters along with their GO categories are represented in Figures 3.103.12 and relate to chromosomal organization (score=1.91, 18 genes: HIST1H2BK,
HIST1H3H, H2BFS, CENPA, TSPYL4, CENPE, TOP2A, HMG20B, ERCC6L,
SYNCRIP, KIF14, MKI67, ZNF226, DNASE1L1, POLQ, KIF15, CDKN1A, PLK4) (Figure
3.10), signaling molecules (score=1.67, 32 genes: AK2, GLRX, UQCRFS1, TMEM2,
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TMEM149, SLC1A3, SDC4, GKN1, LYPD1, NEU1, KIAA1644, ANTXR1, SERPINI1,
CRIM1, CD164, EMR2, ROR2, LRP10, DNASE1L1, CD55, IL10RB, SMPDL3A,
COL9A3, STC2, LUM, SRGN, SMPD1, NRP1, DDR1, DKK3, SFRP1, IGFBP3) (Figure
3.11) and cell cycle (score=1.37, 15 genes: CENPE, KIF11, KIF15, KIF3C, KIF14,
ERCC6L, MKI67, CENPA, CDKN1A, PLK4, TOP2A, LLGL2, HMG20B, DUSP1, AK2)
(Figure 3.12).

Fig. 3.10. Functional annotation of genes significantly regulated by hPNPaseold35
represented as enrichment clusters generated by the DAVID analysis
software. Cluster of 18 genes which were grouped together based on their
involvement in chromosomal organization and related functions. Green corresponding gene-term association positively reported in DAVID; black corresponding gene-term association not reported yet in DAVID.
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Fig. 3.11. Functional annotation of genes significantly regulated by
hPNPaseold-35 represented as enrichment clusters generated by the DAVID
analysis software. Cluster of 32 signaling molecules and cellular receptors.
Green - corresponding gene-term association positively reported in DAVID;
black - corresponding gene-term association not reported yet in DAVID.
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Fig. 3.12. Functional annotation of genes significantly regulated by hPNPaseold-35
represented as enrichment clusters generated by the DAVID analysis software.
Cluster of 15 genes grouped together based on their link to cell cycle-associated functions.
Green - corresponding gene-term association positively reported in DAVID; black corresponding gene-term association not reported yet in DAVID.
	
  

MetaCore™ (GeneGo Inc. USA) analysis of the hPNPaseold-35 responsive genes
resulted in the identification a number of gene interaction networks, two of which are
represented in Figure 3.13 and 3.14. The first network (Figure 3.13) includes 14 genes
(CENPA, CENPE, TOP2A, PLK4, ERCC6L, DDIT4, SFRP1, CRIM1, ZC3HAV1, MVP,
DKK3, FAM134B, LOH11CR2A, and MAGED2) from the list of hPNPaseold-35
responsive genes identified and p53 seems to be a critical player in this signaling
cascade. The second network (Figure 3.14) includes 11 (CENPA, STC2, IGFBP3,
DUSP1, ZC3HAV1, PDZK1, SDC4, NRP1, CDKN1A, RGL1, TOP2A) of the hPNPaseold	
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35

responsive genes, with STAT1 and p21 appearing as major regulatory proteins in this

pathway.

Fig. 3.13. Pathway analysis of hPNPaseold-35 responsive genes. Network
associated with mitosis and involves 14 of our reported hPNPaseold-35 responsive
genes. 	
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Fig. 3.14. Pathway analysis of hPNPaseold-35 responsive genes. Network
associated with p21 signaling and involves 11 of our reported hPNPaseold-35
responsive genes.
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Representative genes in the two networks such as CENPA and CENPE are validated
by qRT-PCR, which are downregulated in response to hPNPaseold-35 overexpression
(Figures 3.15 and 3.16). hPNPaseold-35 stable knockdown in HO-1 and WM35 melanoma
cells resulted in a ~1.2 fold increase in SYNCRIP and a ~1.2-1.6 fold increase in
CENPA potential direct target levels as determined by qRT-PCR (Figure 3.15A-B).
Transient knockdown of hPNPaseold-35 also resulted in a 1.4 fold increase in SYNCRIP
and a ~2 fold increase in CENPA RNA levels in HeLa cells (Figure 3.15C), validating
that this is not a cell line specific effect, nor an indirect effect due to stable knockdown.
Plasmid mediated overexpression of hPNPaseold-35 in HO-1 melanoma cells resulted in
a 20% and 30% reduction in SYNCRIP and CENPA RNA levels respectively (Figure
3.15D). Figure 3.16A shows a graphical representation of the fold decrease in the RNA
levels of CENPA, CENPE and MKI67 following adenoviral mediated overexpression of
hPNPaseold-35 in HO-1 and WM35 melanoma cells in comparison to their respective fold
changes as obtained in the microarray results. Adenoviral mediated overexpression of
hPNPaseold-35 in three different melanoma cell lines (HO-1, WM35 and MeWo) all
resulted in ~40% reduction in CENPA levels (Figure 3.16B).
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Fig. 3.15. Real-time PCR validation of genes identified by microarray analysis. (A)
hPNPaseold-35 –stable knockdown HO-1cells, (B) hPNPaseold-35 –stable knockdown WM35
cells, (C) HeLa cells transiently transfected with siRNA against hPNPaseold-35 and (D) HO-1
cells transfected with pcDNA3.1- hPNPaseold-35. Error bars represent mean ± S.E. of three
independent experiments done in triplicate, statistical significance was determined by a oneway analysis of variance followed by Dunnett’s multiple comparison test and a two-tailed
student’s t-test, *P<0.05, **P<0.01, ***P<0.001.	
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Fig. 3.16. Real-time PCR validation of genes identified by microarray analysis
following Ad.hPNPaseold-35 –mediated overexpression. Error bars represent
mean ± S.E. of three replicate experiments. Statistical significance was determined
by two-tailed student’s t-test, *P<0.05, **P<0.01.	
  
<0.01	
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3.4.4 TCGA correlations of hPNPaseold-35 responsive genes
The Cancer genome atlas (TCGA) database is an enormous repository of gene
expression data from various normal and cancer tissue types. In order to evaluate the in
vivo implications of the hPNPaseold-35	
   responsive genes we identified, we decided to
investigate their potential correlation with hPNPaseold-35	
   in various TCGA datasets. The
genes identified as positively or negatively correlating with hPNPaseold-35	
   expression in
different cancer types are represented in the heat maps shown in Figure 3.17. Prior to
heat map generation, each gene expression value (at log, base 2 scale) for every
sample was transformed by subtracting the average expression across all samples in a
given dataset. As shown in Figure 3.17, the samples in the TCGA OV, COAD, SKCM,
and PRAD cohorts were arranged in order of increasing hPNPaseold-35	
   expression level,
going from green to red. One gene that stood out is DUSP1. As the hPNPaseold-35	
  
expression of OV, COAD, SKCM, and PRAD samples increased, DUSP1 level
decreased (also indicated by negative Pearson correlation coefficients). The Pearson
correlation coefficient (r) between hPNPaseold-35	
  and DUSP1 registered at -0.362. This r
value was 221st lowest (99th percentile) among the 20500 genes whose expression
was related to hPNPaseold-35. As the heat maps indicate, opposite expression trends
(compared to hPNPaseold-35) were observed for the genes KI1644 (OV, COAD, PRAD),
ADARB1 (OV, COAD), HMG20B (COAD), IGFBP3 (COAD, PRAD), DDIT4 (COAD,
PRAD), EMR2 (COAD, SKCM), SLC1A3 (COAD, PRAD), and DHRS2 (PRAD).

In

contrast, the expression levels of the genes GLS (COAD, SKCM, PRAD), LACTB2
(COAD, SKCM, PRAD), MRPS12 (COAD), NEU1 (COAD), CD164 (SKCM), FKBP1B
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(OV), KIF3C (OV), and SFT2D2 (PRAD) exhibited positive correlation with hPNPaseold35
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Fig. 3.17. Heat maps representing correlations of hPNPaseold-35 responsive genes with
hPNPaseold-35 in different tumor types identified using TCGA datasets. (A) hPNPaseold-35
positively and (B) hPNPaseold-35 negatively correlating genes in (i) colon adenocarcinoma
(COAD), (ii) ovarian serous cyst adenocarcinoma (OV), (iii) prostate adenocarcinoma (PRAD),
and (iv) skin cutaneous melanoma (SKCM).	
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3.4.5 Identification of Myc-correlating genes
c-MYC mRNA has been previously shown to be regulated by hPNPaseold-35 at
the post-transcriptional level. Since c-myc is an essential cell cycle regulator and also a
transcription factor implicated in the regulation of expression of numerous genes, we
were interested to identify if genes differentially regulated by hPNPaseold-35 following its
gain or loss of function were in any way under c-myc transcriptional control. Thus, in
order to dissect the potential role of myc in the regulation of hPNPaseold-35 responsive
genes, we identified genes in our two datasets (hPNPaseold-35 knockdown and
overexpression) whose expression correlated with c-myc expression. 31 genes were
identified with expression negatively correlating with c-myc and 29 with expression
positively correlating with c-myc. We further grouped the 60 c-myc correlating genes
into biological categories using the functional annotation cluster analysis tool in DAVID,
which resulted in the identification of 26 gene enrichment clusters with the highest
enrichment score being 2.02. Some of the functional categories identified were
apoptosis (Figure 3.18), DNA repair (Figure 3.19), cytoskeleton (Figure 3.21) and
mRNA processing (Figure 3.22). 11 of c-myc correlating genes identified were also
among the hPNPaseold-35 regulated genes we report here. Of these eleven genes, the
expression of DHRS2, LSM5, STC2, TOP2A positively correlated with c-myc and
IL10RB, LOH11CR2A, MLLT11, MRPS12, NEU1, SMPD1, UQCRFS1 negatively
correlated with c-myc.
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Fig. 3.18. Cluster analysis of functional enrichments for c-Myc correlating
genes. Cluster of 13 genes involved in apoptosis. Green - corresponding geneterm association positively reported in DAVID; black - corresponding gene-term
association not reported yet in DAVID.
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Fig. 3.19. Cluster analysis of functional enrichments for c-Myc
correlating genes. Cluster of 16 genes involved in cytoskeleton
associated functions. Green - corresponding gene-term association
positively reported in DAVID; black - corresponding gene-term
association not reported yet in DAVID.
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Fig. 3.20. Cluster analysis of functional enrichments for c-Myc correlating
genes. Cluster of 13 genes involved in DNA repair. Green - corresponding
gene-term association positively reported in DAVID; black - corresponding
gene-term association not reported yet in DAVID.
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Fig. 3.21. Cluster analysis of functional enrichments for c-Myc correlating
genes. Cluster of 10 genes involved in mRNA processing. Green - corresponding
gene-term association positively reported in DAVID; black - corresponding geneterm association not reported yet in DAVID.
	
  

3.4.6 hPNPaseold-35 overexpression in HO-1 and HeLa cells causes global changes
in cell cycle-associated genes
A comparison between the transcriptome analysis of HeLa cells in which
hPNPaseold-35 was overexpressed by means of a doxycycline-inducible system and
Ad.hPNPaseold-35old-35 infected HO-1 cells revealed 105 differentially regulated genes
(FDR<5%) common among both analyses, some of which are represented in Figure
3.22.
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Fig. 3.22. Genes differentially regulated in response to hPNPaseold-35 overexpression as
identified by microarray analysis in HO-1 and HeLa cells.
	
  

Overall, there were 31 upregulated and 74 downregulated overlapping transcripts
in both studies. In order to classify these genes into biological categories, we made use
of the ToppGene suite of web applications (Table 3.1). The most significant
overrepresented categories were cell cycle, mitosis and DNA metabolism associated
functions.

	
  

112	
  

	
  
Table 3.1. Functional annotation of genes differentially regulated in response to
hPNPaseold-35 overexpression by ToppGene suite.
Functional category

Source

p-value

no. of genes

RNA binding

GO: Molecular Function

1.90E-02

16/857

Cell Cycle phase

GO: Biological Process

5.81E-11

30/864

Mitotic Cell Cycle

GO: Biological Process

1.31E-08

26/785

DNA metabolic process

GO: Biological Process

9.19E-07

25/879

Chromosome

GO: Cellular Component

3.89E-08

21/641

Nucleoplasm

GO: Cellular Component

6.32E-06

28/1483

MSigDB

2.61E-04

14/306

Genes involved in cell cycle,
Mitotic pathway

We also compared the top biological functions (Figure 3.23) and canonical
pathways (Figure 3.24) associated with all the differentially regulated transcripts in both
systems to further understand the global implications of hPNPaseold-35 overexpression.
The most significant biological processes identified by IPA (Ingenuity Pathway Analysis)
were majorly associated with cell cycle-associated functions. More interestingly, most of
the canonical pathways identified in both overexpression systems were also associated
with cell cycle regulatory functions.
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Fig. 3.23. Biological functions identified by IPA corresponding to genes
differentially regulated in response to hPNPaseold-35 overexpression. Hela
pnp = dox-inducible hPNPaseold-35 overexpression, mel adpnp =
Ad.hPNPaseold-35-mediated overexpression.
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Fig. 3.24. Canonical Pathways identified by IPA corresponding to genes
differentially regulated in response to hPNPaseold-35 overexpression. Hela pnp
= dox-inducible hPNPaseold-35 overexpression, mel adpnp = Ad.hPNPaseold-35mediated overexpression.
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3.5 Discussion
In the present study, we have attempted to further unravel the global gene
expression patterns involved with hPNPaseold-35 gain or loss-of-function. We compared
the

gene

expression

changes

resulting

from

hPNPaseold-35

knockdown

and

overexpression in two different cells lines and identified overlapping genes. In the
current analysis we identified 62 hPNPaseold-35 induced and 28 hPNPaseold-35 repressed
genes. Gene ontology analysis of these hPNPaseold-35 induced and repressed
transcripts revealed that a number of them are involved in cell cycle, chromosomal
organization and cellular signaling. We obtained similar evidence in Chapter 2, where
we showed that overexpression of hPNPaseold-35 cause’s global deregulation in cell
cycle-associated genes. Our overlapping analysis helped us to identify genes like
KIF3C [133] and CDKN1A [135], which are transcripts upregulated during growth arrest,
also induced by hPNPaseold-35. Also, a number of genes involved in cellular growth and
proliferation were found to be downregulated like CENPA, CENPE, PLK4, TO2PA, and
POLQ, transcripts repressed by hPNPaseold-35. Further support for this premise was
obtained when we attempted to identify any particular network the hPNPaseold-35
correlating genes interacted in. We were able to identify two networks relating to
mitosis/cell cycle and p21 (a known regulator of growth arrest and cellular senescence)
regulation. From this it can be concluded that hPNPaseold-35 plays a role in cell cycleassociated functions, but future studies would be required in order to gain more
mechanistic insights of this regulation.
Interestingly, some of these genes are common between the overlapping genes
we identified in Chapter 2, MKI67 (a cellular proliferation marker) and CENPE
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(Centromere protein E), which are repressed or negatively correlate with hPNPaseold-35
expression and are important for cellular proliferation. In a way this is a further validation
of the fact that the expression of these transcripts is in some way regulated by
hPNPaseold-35. Another centomeric protein, which is also repressed, CENPA
(Centromere protein A), was identified in this analysis. This finding could be of potential
importance, as CENPA is reported to be a prognostic marker for ER-positive breast
cancer [134] and lung adenocarcinoma [135] and could be a potential therapeutic target
for treatment of cancer and other hPNPaseold-35 associated diseases. Future studies
would be required to further explore this avenue. More interestingly, some of the
hPNPaseold-35 correlated genes we report here were also found to correlate with
hPNPaseold-35 expression in four TCGA normal and cancer tissue datasets we analyzed.
Some of the transcripts identified may provide promising therapeutic leads in terms of
treatment options for certain cancers while harnessing on hPNPaseold-35’s antiproliferative properties. Among these candidates are DUSP1, implicated in promotion of
angiogenesis and metastasis of non-small-cell-lung cancer [136]; ADARB1, reported to
be upregulated in numerous carcinomas [137-139]; EMR2, associated with poor
prognosis in glioblastoma [140]. Although identification of these transcripts provides
valuable future options for treatment of cancer and possible other diseases, the
mechanism of hPNPaseold-35 regulation of these genes would need to be elucidated, i.e.
are they directly degraded by hPNPaseold-35 (hPNPaseold-35 repressed genes) or do
specific miRNAs control their expression which in turn hPNPaseold-35 regulates
(hPNPaseold-35 induced genes).
c-myc is a transcription factor involved in the regulation of numerous cellular
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processes including but not restricted to apoptosis, cell cycle and metabolism, and most
of the c-myc correlated genes we report here are associated with apoptosis, cell cycle,
mRNA processing and DNA repair gene ontology categories. c-myc mRNA is also
targeted by hPNPaseold-35 for exoribonucleolytic degradation, thus arises the complexity
in our analyses of hPNPaseold-35 regulated gene expression changes. To this end we
performed our microarray analyses at an early timepoint of 24 hrs following hPNPaseold35

overexpression, before c-myc levels started to deplete, but a small change of -1.4 fold

was still evident in our microarray analyses following hPNPaseold-35 overexpression.
Thus, we wanted to confirm if there were transcripts we identified as being hPNPaseold35

regulated that were also c-myc target genes. A search of the Myc target gene

database

(http://www.myccancergene.org)

involving

the

11

c-myc

correlated/

hPNPaseold-35 responsive transcripts did not reveal any report of the direct regulation of
these genes by c-myc transcription factor. Thus, at this time we cannot claim that the
expression correlation of these transcripts with c-myc means that they are its targets.
Future studies involving a search of c-myc binding sites in the promoter region of these
transcripts may provide concrete information regarding this premise. Until then it would
be safe to proclaim that gene expression changes induced by hPNPaseold-35 may
involve numerous other regulatory factors causing global changes in cell cycleassociated functions, apart from hPNPaseold-35’s direct degradation of mRNA and
miRNA species.
Finally, we compared the gene expression profiles of two different cell lines in
which we overexpressed hPNPaseold-35 using two different mechanisms, a doxycyclineinducible expression vector and an adenoviral vector. We not only observed 105
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overlapping genes between both systems, but interestingly almost all these genes were
associated with cell cycle, mitosis and chromosomal functions as identified by gene
ontology categories. Apart from the overlapping genes, comparative pathway analysis
of both the hPNPaseold-35 overexpression datasets revealed that the most significant
affected pathways were related to cellular growth and proliferation. Since there was
such a strong correlation of this gene list with cell cycle associated functions we wanted
to evaluate whether any of these genes were targets of c-myc transcription activation or
repression. A search for these genes in the c-myc target database mentioned earlier
revealed that 28 of these genes were predicted targets of c-myc. Out of these 28 genes,
four of the downregulated genes (E2F3, PTMA, DDX18 and TFRC) were also identified
by ToppGene suite as validated targets of c-myc transcriptional activation (Table 1).
Thus, at this time we can say that overexpression of hPNPaseold-35 may be associated
with global regulation of cell cycle associated functions, as evidence is provided by the
global deregulation of numerous genes involved in these events, although some of
these changes could be associated with c-myc downregulation. In the event of
hPNPaseold-35 overexpression, upregulation of pro-apoptotic molecules like FAS and
downregulation of genes essential for cellular proliferation like E2F3, MCM4, MCM7 and
EIF4G1 may tip the balance towards growth arrest. Whether hPNPaseold-35 directly
degrades these transcripts (in vitro degradation assays would provide the ultimate proof
for this hypothesis) or whether these are downstream events of a few preliminary events
(like downregulation of c-myc eventually resulting in the cascade of events leading to
growth inhibition) remains to be answered in the future studies performed in a c-mycnull background.
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CHAPTER FOUR

Analysis of sequence specificity for degradation by hPNPaseold-35

4.1 Abstract
Previous studies have established that c-myc mRNA is a direct degradation
target of hPNPaseold-35. Over-expression of c-myc devoid its 3’UTR partially but not
completely protects HO-1 cells from the growth-inhibitory effects of Ad.hPNPaseold-35
infection. Other RNA species like c-jun and GADD34 are not degraded, suggesting that
c-myc mRNA is a very specific target of hPNPaseold-35 degradation. This may be due to
the presence of specific sequence or secondary structural elements in the 3’UTR of cmyc mRNA. The primary aim of this study is to address this question.
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4.2 Introduction
One of the molecular mechanisms elucidated responsible for the growth
inhibitory properties of hPNPaseold-35 in cancer cells was found to be selective
degradation of c-myc mRNA [48]. This has been proven by in vitro mRNA degradation
assays also, where hPNPaseold-35 could specifically degrade c-myc mRNA, but not other
mRNAs such as c-jun, GAPDH or GADD34 [29,48]. Specific RNA cis elements have
been identified which affect the stability and/or translation of given subsets of mRNAs.
Within the 3’UTR, the most commonly found cis elements determinants of mRNA
turnover and translation are AU rich elements (AREs). The 3’UTR of c-myc mRNA has
four such instability elements. It would be important to understand whether the presence
of these ARE elements provides a specific sequence identification element or
secondary structure that allows its degradation by hPNPaseold-35. Also, further
sequence/secondary structure homology searches identifying similar mRNA species
would be helpful in finding other hPNPaseold-35 target genes.
4.3 Materials and Methods
4.3.1 Construction of c-myc 3’UTR deletion mutants
In order to evaluate the importance of each of the four AU rich elements in the
3’UTR of c-myc mRNA and the role they may play in degradation by hPNPaseold-35, five
sequential deletion constructs including the coding sequence and parts of the 3’UTR of
c-myc were constructed (M1-M5). The specific 3’UTR deletion fragments were PCR
amplified with specific primers using a human cDNA clone (ORIGENE) as template and
subcloned into pGEM-Teasy vector (Promega). Subsequently, the fragments were
digested with the help of EcoRI and XbaI restriction endonucleases and religated into
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pcDNA 3.1/Hygro (+) expression vector. The sequences of all the constructs were
verified before transfection. A diagrammatic representation of the deletion constructs
M1-M5 is provided in Figure 4.1.

Fig. 4.1. Schematic representation of c-myc 3’UTR deletion constructs.
	
  

4.3.2 Colony Formation Assays
HO-1 cells were plated at a density of 2 x 105 cells/6-cm dish and 24 h later were
transfected with 4 µg of either empty vector or plasmids M1-M5 using LipofectamineTM
2000 (Invitrogen) transfection reagent according to the protocol from the manufacturer.
After 36 h, the cells were infected with Ad.Vec or Ad.hPNPaseold-35 at a multiplicity of
infection (m.o.i.) of 5000vp/cell; 6 h later, the cells were trypsinized and counted and 103
cells were plated in 6-cm dishes in triplicate. Colonies were visualized by Giemsa
staining and counted after 3 weeks.
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4.4 Results and Discussion
Previous studies have shown that c-myc mRNA is a direct degradation target of
hPNPaseold-35 [29,48,60], which is also one of the molecular mechanisms involved in
hPNPaseold-35 mediated growth arrest. The specificity of this degradative effect lies in the
3’UTR sequence of c-myc mRNA as shown by rescue experiments in which growth
inhibition caused by Ad.hPNPaseold-35 infection could partially be rescued by
overexpression c-myc devoid its 3’UTR [48]. As an extension of this interesting finding,
3’UTR deletion mutants of c-myc were generated (Figure 4.2) to identify any specific

	
  

Fig. 4.2. Schematic representation of the cloning strategy used for the
generation of the c-myc 3’UTR deletion constructs.
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regions in the 3’UTR of c-myc mRNA that could be required for degradation by
hPNPaseold-35. In order to evaluate this hypothesis, HO-1 cells were transfected with the
five 3’UTR deletion constructs (M1-M5), infected with Ad.hPNPaseold-35 and the growth
of cells was analyzed by colony formation assays after a period of 3 weeks (Figure 4.3).
We observed that growth suppression caused by adenoviral-mediated hPNPaseold-35
overexpression could be partially rescued by c-myc-3’UTR deletion constructs M1
(28%, offers most protection as it is completed devoid of the 3’UTR), M2 (23%), and M3
(17%) (Figure 4.4). Transfection with M4 resulted in >80% growth inhibition in
conjunction with Ad.hPNPaseold-35 infection and M5 transfection resulted in only a ~10%
rescue in growth followed by Ad.hPNPaseold-35 infection as compared to constructs M1M3, as shown in Figure 4.4. Based on these preliminary results we can presume that
the region between 1562 and 1787bps (sequence present in constructs M4, M5 and
deleted from constructs M1-M3) in the 3’UTR sequence of c-myc could possess
recognition sequences or secondary structure elements necessary for hPNPaseold-35
mediated degradation thus eliminating the growth protection rendered by constructs M1M3 (which do not possess the specific sequence region and are protected from
hPNPaseold-35 degradation). Also, since M5, which has the complete 3’ UTR, provided
more protection than M4 (which has region 1639-1787 deleted), it can be presumed that
the specificity of degradation by hPNPaseold-35 is most likely dependent on secondary
structural elements rather than primary sequence alone. These results would need to be
further validated as although done in technical triplicates, these results are based on
one biological experiment. Future experiments involving in vitro transcription of these
deletion fragments followed by hPNPaseold-35 in vitro degradation assays would need to
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be performed to analyze whether fragments M1-M3 are indeed protected from
hPNPaseold-35 degradation and whether fragments M4, M5 are degraded by hPNPaseold35

.

Fig. 4.3. Growth rescue experiment. HO-1 cells were plated at a density of 2 x 105
cells/6-cm dish and 24 h later were transfected with 4 µg of either empty vector or cmyc 3’UTR deletion constructs M1-M5. After 36 h, the cells were infected with
Ad.Vec or Ad.hPNPaseold-35 at a multiplicity of infection (m.o.i.) of 5000vp/cell; 6 h
later, the cells were trypsinized and counted and 103 cells were plated in 6-cm dishes
in triplicate. Colonies were visualized by Giemsa staining and counted after 3 weeks.
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Fig. 4.4. Graphical representation of colony numbers as described in
Fig. 4.3. The data represent mean ± standard error of one experiment done
in triplicate, statistical significance was determined by two-tailed student’s ttest, *P<0.05.
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CHAPTER FIVE

Evolutionary dynamics of Polynucleotide phosphorylases
Part of the work presented in this chapter has been submitted for publication in
Molecular Phylogenetics and Evolution (2013).

5.1 Abstract
Polynucleotide phosphorylase (PNPase) is an evolutionarily conserved 3’→5’
phosphate-dependent exoribonucease belonging to the PDX family of proteins. It
consists of two catalytic RNase PH domains (PNP1 and PNP2), an α-helical domain
and two RNA-binding domains. The PNP1 and PNP2 domain share substantial
sequence and structural homology with RNase PH (RPH), which is another PDX family
member found in all the three major kingdoms of life, suggesting that these three
domains originated from a common ancestor. Phylogenetic analysis (based on the
PNPase /RNase PH sequence information for 43 vertebrate taxa) shows that PNP2 and
RPH are sister taxa which arose through duplication of the ancestral PNP1 domain.
Also, all three domains (PNP1, PNP2 and RPH), along with the KH and S1 domains
have undergone significant and directional sequence change, as determined by branch
and site-specific dN/dS analyses. In general, codons that show dN/dS ratios that are
significantly greater than 1.0 are outside the ordered regions (α-helices and β-sheets) of
these protein domains. In addition, sites that have been selected for mutagenesis in
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these proteins lie embedded in regions where there is a preponderance of codons with
dN/dS values that are not significantly different from 0.0. Overall, this report is an
attempt to further our understanding of the evolutionary history of these three protein
domains, and define the evolutionary events that led to their refinement in the vertebrate
lineage leading to mammals.
5.2 Introduction
RNA metabolism plays a significant role in the post-transcriptional control of gene
expression in both prokaryotic and eukaryotic organisms [12]. Key players involved in
the decay and processing of various RNA species are a special class of enzymatic
proteins called ribonucleases (RNases) [37,141]. Based on their degradative functions,
RNases

are

divided

into

endo-

and

exo-ribonucleases

[13,93].

One

such

exoribonuclease is polynucleotide phosphorylase (PNPase), which is an ancient
enzyme that has been evolutionarily conserved in all the kingdoms of life, although it is
absent in Archaea and certain single cell eukaryotes [91]. Functionally, it is a 3’→5’
phosphorolytic exoribonuclease belonging to the PDX family of proteins [4,14]. The PDX
family includes RNase PH, another phosphate-dependent exoribonuclease. Considered
the simplest member of the PDX family, RNase PH was first identified in E.coli [28,142],
and its orthologues are found in all kingdoms [91]. The main difference between RNase
PH and PNPase is that in vivo, RNase PH is involved in the processing of tRNA
precursors and in the digestion of structured RNA in bacteria [142,143], whereas
PNPase mainly plays a role in mRNA degradation [16,48].
Sequence alignment shows that PNPases from various kingdoms share a
classical domain structure consisting of: two N-terminal RNase PH domains (containing
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the PDX catalytic sites, designated PNP1 and PNP2), an α-helical domain between
PNP1 and PNP2, and the RNA-binding domains KH (K-homology) and S1 domain
located at the C-terminal (Figure 5.1) [13,18,19].

Fig. 5.1. Schematic diagrams of PNPase (old-35) and RPH showing the various
domains in these proteins. The domain name is given above the diagram and the
length of the domain is given below the diagram.
	
  

Both RNase PH and PNPase form ring-like structure (hexameric and homotrimeric
respectively) with a central channel in its active form. The level of structural and
sequence similarity between the PDX domains in PNPase and RNase PH raises the
possibility that these domains may have originated from a common ancestor (in the
most recent common ancestor of life; MRCA) via gene duplication events [91,93].
Previously, our primary focus has been to analyze how the three PDX domains
(PNP1, PNP2 and RPH) have evolved in the tree of life. However, recent structural and
phylogenetic information on these domains has made possible the examination of the
evolutionary dynamics of their function. One common tool that is used to examine
functional significance of proteins over evolutionary time is to characterize the impact of
natural selection on sequence change.
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patterns of natural selection in a phylogenetic context on a residue by residue basis, as
well as on a branch by branch basis in a phylogeny are well developed [144-147]. They
are based on corrected assessment of the ratio of nonsynonomous to synonymous
substitutions over evolutionary time. The null hypothesis in such studies is the situation
where the nonsynonymous to synonymous changes are equal in abundance.

A

statistically

to

significant

overabundance

of

nonsynonymous

change

relative

synonymous change is usually taken as an indication of positive natural selection. And
a significant lack of nonsynonymous change to synonymous change has been taken as
evidence for negative or purifying selection by researchers.
These approaches have been criticized on statistical grounds [148] and on the
grounds that statistical demonstration of selection is only the first step in understanding
natural selection on proteins.

In other words, once natural selection has been

suggested by statistical methods it should also be tested in a functional or biochemical
context [148,149].
Here, we use the well known functional and structural characteristics of the PNP
and RPH domains to examine the validity of statistically determined measures of natural
selection.

Several sites in PNPases have been mutagenized and the functional

significance of those mutations has been well characterized. In addition, sequence
integrity is an invariable factor [148], but recent advances in structural biology show that
secondary structure is equally important in not only determining the functionality but
also in dictating the rates of site-specific evolution of proteins [150]. These residues
under natural selection (positive or negative) may occur in ordered (α-helices and βsheets) or disordered (random coils and turns) regions [151]. However, from our
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analyses of PNP1, PNP2 and RPH sequences from 43 eukaryotic taxa (Table 5.1), we
can infer that the residues with dN/dS measures greater than 1 are almost entirely
found outside of α-helices and β-sheets. Finally, through phylogenetic analysis, we have
been able to discern the possible time course of evolution and molecular events when
PNPase (PNP1, PNP2, KH and S1) and RPH domains might have been under positive
natural selection among vertebrates.
Table 5.1. Taxa used in the study
Deuterostome
Mammals

Carnivora
Rodentia

Marsupials
Lizards/Birds
Amphibia
Fish
	
  

Primates
Homo
Pan_
Papio
Macaca
Nomascus
Otolemur
Calithrix
Saimiri
Felis
Canis
Ailuropoda
Cricetulus
Mus
Rattus
Cavia
Oryctolagus
Sus
Bos
Equus
Loxodonta
Monodelphis
Sarcophilus
Ornithorhy
Gallus
Taeniopygia
Anolis
Xenopus
Takifugu
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Danio
Oreochromis
Other deuterostome
Branchiostoma
Protostome
Insect
Nematode
Worm
Lower Metazoa
Plant

Drosophila
Tribolium
C.elegans
Brugia
Amphimedon
Trichoplax
Nematostella
Arabidopsis
Physcomytrella
Selaginella

5.3 Materials and Methods
5.3.1 Sequences and Matrix construction
PNPase and RNase PH sequences were obtained from Genbank using a
taxonomic sampling strategy to cover the eukaryotic tree of life. Only PNPase and
RNase PH sequences from fully sequenced and accurately annotated eukaryotic
genomes were used. A list of the taxa used in this study is given in Table 5.1. Codon
sequences were obtained in all cases and accession numbers for the sequences are
given in Table 5.1. Sequences were aligned in TranslatorX [152] a program that aligns
codons using amino acids as a guide. For the various analyses in this paper we
generated several different phylogenetic matrices that were used in tree building and
natural selection detection programs. The first kind of matrix we generated was a
taxonomic based matrix with the 43 taxa we list in Table 5.1. This matrix consists of fulllength PNP sequences concatenated with RNase PH sequences for the same 43 taxa
in a NEXUS formatted matrix. The different regions of the PNPase genes and the RPH
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gene (Figure 5.1) were then partitioned using NEXUS commands in the NEXUS matrix.
The root of this matrix was established using the three plant taxa (Arabidopsis,
Selaginella and Physcomytrella) as outgroups.
The second kind of matrix combined PNP1, PNP2 and RPH domains from all 43
taxa used in this study. This matrix was constructed using a separate alignment
procedure from the taxonomic-based matrix. In addition two RNase II genes (one from
human and the other from Trichoplax) were used to root trees for this latter matrix.
5.3.2 Phylogenetic analysis
Phylogenetic trees were constructed using parsimony, maximum likelihood and
Bayesian approaches [153]. The model used was a GTR with invariants rates and
gamma distribution (estimated from the data set). 100 bootstrap replicates were
performed when bootstrapping (either MP or ML) [154]. Bayesian analysis was
performed using 1 million generations of simulation and the model described above. For
the selection analyses we used a predetermined tree topology based on the wellaccepted taxonomy of the organisms in the study [155].
5.3.3 Detecting the Statistical imprint of skewed dN/dS ratios
For the selection analyses we used a predetermined tree topology based on the
well-accepted taxonomy of the organisms in the study [146]. Two tests were used to
detect statistically significant patterns of skewed dN/dS ratios. The first test determines
the branches in the accepted phylogeny where statistically significant departure from
neutral evolution occurs. The BREL (Branch-site Random Effects Likelihood) test in the
HyPhy [156] package was used on the three domains for the taxon based matrices
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(PNP1, PNP2 and RPH) separately. In addition, the BREL option was also used to
analyze branch specific natural selection in the matrix with all three-domain sequences
as terminals. The default settings and the accepted tree topology were used in these
tests [157,158].
The second test implemented the MEME (Mixed Effects Model of Evolution)
[159] option in DataMonkey, the web version of HyPhy [157,159]. This option uses
mixed model approaches to detect departure from neutrality at individual codons. This
latter test was performed individually on each of the three domains – PNP1, PNP2 and
RPH.
5.3.4 Mapping Sites with dN/dS Skew Onto Secondary and Tertiary Protein
Structure
The

NIH-NCBI

Structure

Summary

MMDB

(http://www.ncbi.nlm.nih.gov/Structure/MMDB/mmdb.shtml) was used to map residues
onto the tertiary structure of PNPase and RNasePH proteins. The CN3D software
(http://www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml) was used to visualize tertiary
structure. This program allows for the selection of residues previously determined as
under positive natural selection using the “Select Columns” option. Once these residues
are selected their position in the three dimensional model of the protein are marked by
yellow “slivers”. The CN3D structures presented are for the trimeric conformation of the
protein.
The secondary structure of these two proteins was mapped using the RCSBPDB web browser (http://www.rcsb.org/pdb/home/home.do) using the “Sequence”
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pulldown menu. This web browser produces a linear model of the proteins with regions
corresponding to alpha helices, beta sheets and other critical secondary structures
marked on the sequence. For obtaining both the tertiary and secondary structures of
these proteins the human sequence was used as a guide.
5.4 Results
5.4.1 Phylogenetic relationships of PNP domains
The matrix with domains as terminals yielded a tree where the different PNP
domains are monophyletic with respect to one another (Figure 5.2). In addition, the root
of the Bayesian domain tree indicates that PNP1, PNP2 and RPH cannot be
determined. However, both maximum parsimony and maximum likelihood recover a tree
wherein PNP2 and RPH are sister taxa (root at arrow in Figure 5.2), as previously
reported by Leszczyniecka et al., (2004) [91]. This rooting indicates that the PNP1
domain appeared first in the genomes of the common ancestor of all life, and that PNP2
and RPH arose as the result of subsequent duplication events. This rooting lacked
robustness since the out-groups (human and trichoplax RNase II) are quite distant from
the in-group domains. Large out-group distances can result in random rooting [160] on
the in-group and this may explain why the Bayesian analysis fails to recover a more
resolved root for the domain tree.
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Fig. 5.2. Bayesian phylogenetic tree showing the relationship of the three major
domains (PNP1, PNP2 and RPH) examined in this study.
	
  

5.4.2 Branch Specific Skew in dN/dS ratios
The BREL test in HyPhy detected several branches in the backbone of the
vertebrate phylogeny leading to mammals that show significant departure from a dN/dS
ratio of 1.0 (Figure 5.3). Specifically all of the seven branches in the tree in Figure 5.3,
leading to mammals from the common ancestor of Branchiostoma and true vertebrates
show a shift in intensity of this skew. Of these seven branches, three are impacted by
skewed ratios in PNP1, two in PNP2 and three in RPH. There are only two other
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regions of the tree where two of the genes exhibit skew of this ratio. One region involves
the lineage leading to protostomes (i.e. insects and nematodes), and the other, the
lineage leading to Bos and Sus (bovids and pigs). These results suggest a major shift in
sequence dynamics and subsequent stabilization of the evolution of these protein
domains as vertebrates, fish and mammals evolved.
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Fig. 5.3. Tree of animal life using plants as an outgroup showing which
branches on the tree have experienced positive dN/dS skew. The domains that
are under selection are shown in colors and the nodes where positive skew exists
are colored accordingly for the different domains. The dotted lined box indicate the
region of the backbone in the tree leading from primitive vertebrates to mammals
where positive dN/dS skew has occurred in the four domain regions we examined.
	
  
5.4.3 General Site-specific Skew in dN/dS ratios in PNP domains
The MEME analyses of PNP1, PNP2, RPH and the KH domains (Figure 5.4A)
indicate that the sites experiencing positive dN/dS skew are generally outside of αhelices and β-sheets (Figure 5.4B). Surprisingly, RPH appears to have twice as many
sites that are positively skewed compared to PNP1 or PNP2 (Figure 5.4B).
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Fig. 5.4. Site-specific positive dN/dS skew in the three PNP domains
(PNP1, PNP2 and RPH) and the KH and S1 domain. (A) The cartoons
show the location of α-helices (green), β-sheets (tan), and the S1 region
(yellow). Also indicated are the specific locations of sites that have skewed
dN/dS ratios (red lines). (B) Bar chart showing the number of sites in betasheets and alpha helices under positive skewed dN/dS. The green bars
show the number of sites that are either not in sheets and helices or on the
very edge of a sheet or helix. The red bars show the number of sites that
have positive skewed dN/dS that are squarely within alpha helices. There
were no sites positive skew found squarely in beta sheets. 	
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All of the RPH sites that show positive skew are in the N-terminus of the protein. In
contrast, the sites with positive dN/dS ratios in the PNP domains are oftentimes in the
C-terminus, which might impact how the helices and β-sheets in the domains make
turns. The S1 domain consists primarily of β-sheets with four skewed sites at the Cterminus, outside of the sheets (Figure 5.4). In total, 17 sites in all of these domains with
positively skewed dN/dS ratios are either outside of sheets and helices or in the first
residue of a sheet or helix. Only three sites with positive skew lie squarely within alpha
helices, and none within the beta sheets. Secondary structure plots indicating sites
experiencing positive dN/dS skew in PNP1, PNP2, KH/S1 and RNase PH are provided
in Figures 5.5 and 5.6.
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Fig. 5.5. Secondary structure plot indicating sites under positive
selection in PNP1, PNP2 and KH/S1 (sites highlighted as green
circles).
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Fig. 5.6. Secondary structure plot indicating sites under positive selection in RNase
PH (sites highlighted as green circles).
	
  
5.4.4 Correlating skewed dN/dS with structural variants
The locations of residues with significant dN/dS>1.0, relative to the protein’s
three-dimensional structure were visualized through the use of the CN3D software.
Most of the skewed sites (yellow linings) in the PNP1, PNP2, and KH/S1 domains of
PNPase (Figure 5.7), as well RNase PH (Figure 5.8) are either outside or at the edges
of ordered secondary structures.
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Fig. 5.7. 3-D visualization of positively selected sites in PNP1, PNP2 and KH/S1
using the CN3D software. The upper left panel shows the three dimensional crystal
structure of the human PNPaseold-35 protein. Each of the subsequent panels shows
the position of sites under natural selection (yellow slivers). Helices that have sites in
the middle or on the edge are visualized with this software as well as the position of
sites that are not in helices or sheets.
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Fig. 5.8. 3-D visualization of positively selected sites in RNasePH using the
CN3D software. The left panel shows the three dimensional structure of the human
RNase PH protein. The panel on the right shows the position of sites under natural
selection (yellow slivers). Helices that have sites in the middle or on the edge are
visualized with this software as well as the position of sites that are not in helices or
sheets.
	
  

Next we compared the positions of residues that cause known structural variation

via mutagenesis with their dN/dS ratios. Because the functional significance of the
mutagenized residues is known this comparison allows us to examine possible
correlations of significant dN/dS values with function. Since most of the mutagenized
sites were chosen to disrupt function, we do not expect a direct correlation of
significantly skewed dN/dS ratios with mutagenized site. In fact, we hypothesize that
mutagenized sites disrupting function should be under intense purifying selection, and
have no significant dN/dS ratios. For the most part this is what we observe, and in
addition, it appears that many of the sites chosen for mutagenesis are embedded in
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regions of these domains that show dN/dS ratios that are not significantly different from
0.0 (an indication of strong negative or purifying selection). There are some exceptions.
PNPase domains: Table 5.2 lists the residues in PNP domains that have been
mutagenized and the functional significance of the variation along with the sites
detected in this study with statistically significant dN/dS ratios > 1.0. The only extreme
overlap of positively skewed dN/dS ratio with a site mutagenized that alters function is
S483 a dN/dS > 1.0 site which is a binding site for Citrate D 670 located near the active
site.

This significant dN/dS site is right next to the S484 mutagenesis site, which

abrogates polymerization and degradation activities of hPNPase. The juxtaposition of
these two sites is interesting and it could be hypothesized that the S483 dN/dS site
might have been involved in the evolution of this function. P519 a site that has a dN/dS
ratio > 1.0 is also the position of a somatic mutation (P519T) found in hPNPase that was
identified through the COSMIC (http://cancer.sanger.ac.uk/cosmic) database. This site
is not observed as a mutated site in human populations with any significant frequency,
but it could be hypothesized that this site is important for a derived hPNPase function in
normal human or primate tissues and this function may be disrupted after the mutation
found in a cancer patient (P519T). This might be a very interesting residue to work with
in the future and would have to be validated in future in vitro experiments. Since this
residue is solvent exposed, it could be a site required for interaction with other proteins,
a premise that would also need further verification.
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Table 5.2. PNP domains comparison of significant dN/dS with mutagenized sites.

	
  

Domain

Conserved
residues

PNP1 or 2

wt

PNP1

D135G

PNP1

dN/dS
residues

Function
affected

Ref.

pol ++ / deg ++

[30,44]

14 X 12

pol - / deg -

[30,44]

n

S211

?

PNP1

n

V247

?

PNP1

n

T266

?

PNP1

n

V268

?

PNP2

n

F377

?

[161]

PNP2

Q387R

9 x 16

Blocks trimer
formation,
mtRNA
import, mt
translation

PNP2

R445E

19 XX 12

pol +++ / deg +

[30,44]

PNP2

R446E

18 XX 11

pol +++ /deg +

[30,44]

PNP2

E475G

17 X 7

Blocks trimer
formation

[108]

PNP2

S484A

S483

pol - deg -

[30,44]

PNP2

D538A

15 X 5 X 26

pol + /deg +

[30,44]

PNP2

D544G

15 X 5 X 26 pol +++ / deg +

PNP2

n

P519

?
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[30,44]
Somatic mutation
(COSMIC database)

	
  

PNP2

n

?

N590

Red lettering = mutagenized sites and green lettering positively skewed dN/dS sites.
Green shading = two codons adjacent to each other R445 and R446. Blue shading
marks two codons within six codons of each other D538 and D544. The notation for
dN/dS for conserved mutagenized sites is nXm, where X indicates the position of a
mutagenized codon and n indicates the number of residues toward the amino end of the
protein that have dN/dS = 0.0, and m indicates the number of residues toward the
carboxy end of the protein that have dN/dS = 0.0

RPH domain: The sites with dN/dS>1.0 at the amino terminal of this domain are
interspersed with several sites that have been altered by mutagenesis (Table 5.3). The
first 22 or so residues appear to be very important in maintaining the structural integrity
of the domain and both mutagenized and skewed dN/dS sites exist here. This result
could point to the importance of this region in maintaining the structural integrity of the
domain. The remainder of the residues in this domain behaves, as we would predict.
Any mutagenized residue appears to be embedded in long stretches of sites with dN/dS
ratios not significantly different from 0.0, indicating a strong tendency toward
conservation of sequences and of function. Any sites showing positively skewed dN/dS
> 1.0 are outside of these highly conserved regions.
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Table 5.3. RPH Comparison of significant dN/dS with mutagenized sites.
Conserved
residues

dN/dS
residues

Function

Ref.

R12

Y11

structural

[162]

D14

D14

structural

[162]

R16

G15

structural

[162]

R22

5X5

structural

[162]

n

G36

?

n

A38

?

n

T45

?

R61

11 X 10

RNA-binding
(RNA entry site)

[162,163]

A62

12 X 9

RNA-binding
(RNA entry site)

[162,163]

n

C73

?

n

F80

?

n

E84

?

3 XX 3 X 12

RNA-binding
(RNA exit site)

R93

K94

RNA-binding
3 XX 3 X 12 (RNA entry site)

E97

3 XX 3 X 12

RNA-binding

[162]

22 X 3 X 40

phosphatebinding

[162]

22 X 3 X 40

phosphatebinding

[162]

D130
T133

	
  

[162,163]
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[162,163]

	
  
D171

40 X 4 XX 31

catalytic

[162]

E176

40 X 4 XX 31

catalytic

[162]

E177

40 X 4 XX 31

catalytic

[162]

Red lettering = mutagenized sites and green lettering positively skewed dN/dS sites.
Green shading two codons adjacent to each other. Different shading indicates sites that
are in close adjacency to one another. The notation for dN/dS for conserved
mutagenized sites is nXm, where X indicates the position of a mutagenized codon and n
indicates the number of residues toward the amino end of the protein that have dN/dS =
0.0, and m indicates the number of residues toward the carboxy end of the protein that
have dN/dS = 0.0

KH domain:

Two residues in the KH domain identified as having positively

skewed dN/dS ratios, T635 and I667, are highly conserved [31], and located around the
pore of the trimeric protein near residue G622 (Table 5.4) which has been shown to be
important for RNA binding [31]. Again these may be positions that show strong positive
selection because of recent acquisition of function. In addition, two other sites might be
involved in trimer formation - S211 and A633. It could be that these are important for
trimer formation or RNA binding as suggested by their location and evolutionary
conservation, but this again would need to be tested by extensive mutation analysis and
biochemical assays.
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Table 5.4. KH domain comparison of significant dN/dS with mutagenized sites.
Domain

Conserved
residues

dN/dS
residues

Function

Ref.

KH/S1

G622D

10 X 10

RNA binding lost

[31]

KH/S1

n

A633

?

KH/S1

n

T635

pore of the trimeric protein

KH/S1

n

I667

pore of the trimeric protein

Red lettering = mutagenized sites and green lettering positively skewed dN/dS sites.
The notation for dN/dS for conserved mutagenized sites is nXm, where X indicates the
position of a mutagenized codon and n indicates the number of residues toward the
amino end of the protein that have dN/dS = 0.0, and m indicates the number of residues
toward the carboxy end of the protein that have dN/dS = 0.0

5.5 Discussion
There are two evolutionarily conserved members of the PDX family of proteins:
RNase PH and PNPase. The RNase PH protein is the simplest 3’→5’ phosphorolytic
exoribonuclease which can be considered as a prototype of the PDX family of proteins
[4,14]. Within PNPase are the catalytic domains PNP1 and PNP2, which share
significant sequence similarity with RNase PH. The evolutionary origin of RNase PH can
be traced in a straightforward manner because it exists in bacteria, and has orthologues
in Archaea and Eukarya. Its ubiquitous phylogenetic distribution exemplifies the
functional importance of this ribonuclease. In contrast, PNPase is absent in all Archaea
and single cell eukaryotes such as yeast [13,91,93]. The prevalent phylogenetic
distribution of these proteins and sequence similarity between them raises the
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possibility that the PDX domains of PNPase (PNP1 and PNP2) and RNase PH arose
via gene duplication events from a common origin (i.e. the most recent common
ancestor; MRCA) [91,93].

The current study attempts to address where in the

phylogenetic history did major sequence changes appear that might have shaped the
important functions of these domains.
Domain evolution in PNPases: Phylogenetic analysis performed in this study, using
sequences of RNase PH, PNP1 and PNP2 domains from 43 eukaryotic taxa, confirms a
previous finding that PNP2 and RPH are more closely related to each other (i.e. sister
taxa), with PNP1 having diverged from the PDX domain family earlier in evolution
[91,93]. The rooting of parsimony and likelihood trees specifies PNP1 as the domain
that appeared in the genomes of the Most Recent Common Ancestor (MRCA) of life.
This is consistent with the PNP1 “first” hypothesis being the most parsimonious and
likely scenario. This being the case, it seems safe to assume that PNP2 and RNase PH
arose as a result of duplication events. If RNase PH emerged only during later stages of
evolution, it is important that we explain the presence of its orthologues in all kingdoms
of life, while PNPase is absent in all Archaea and a number of other organisms. There
are two likely explanations. First, the terminally duplicated RNase PH domain could
have been transferred to Archaea by horizontal gene transfer (HGT) via the common
Eukaryote ancestor. Second, the full-length PNPase might have been lost in the
Archaeal lineage. The “node height test” predicted that the lineage extinction of PNPase
in Archaea is the more acceptable sequence of events, which occurred during the
evolution of these domains [91,164]. In any case, the series of events or the kinds of
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selective pressure that may have factored in this evolutionary process are still under
speculation.
Branch Specific Sequence Skew:

For PNPase and RNase PH, a deeper

understanding of the process of sequence change during their evolution, may translate
to better insights regarding the proteins’ conserved (and evolved) functionalities. Using
the Branch-site Random Effects Likelihood (BREL) and Mixed Effects Model of
Evolution (MEME) analytical tools, we were able to identify previously unknown branchand site-specific departures from dN/dS=1.0 related to the PNP1, PNP2, KH, S1 and
RPH domains [158,159].

When a codon has a dN/dS ratio that is statistically

significantly greater than 1.0 we call this positive skew. BREL analyses led to the
detection of lineage specific positive skew relating to all the five domains during
vertebrate evolution. The advantage of this approach is its ability to infer episodic skew
events on branches in a phylogeny. Moreover, this tool helped us identify the three
branches of the phylogeny of animals exhibiting a significant positive skew in dN/dS.
The first branch is the lineage leading to Protostomes (the lineage that is sister to the
large clade that vertebrates belong to) where both PNP1 and KH/S1 show positive skew
once. The second region comprises seven branches in the vertebrate phylogenetic tree
leading to mammals from the common ancestor of Branchiostoma, with all of them
exhibiting significant positive skew in one or more of the domains of PNPase and
RNasePH. The third branch is the lineage leading to Bovids where both PNP2 and
RPH show positive skew once. As pointed out earlier, the inference we can draw from
these findings is that all four protein domains PNP1, PNP2, RPH and KH/S1
experienced positive skew during sequence evolution leading to the vertebrates, after
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which the analysis suggests stabilization of the domains leading to higher mammals.
While we cannot at this point in time claim that natural selection was at work in molding
these domains in the common ancestor of the vertebrates, we can point to the fact that
some highly skewed sequence change occurred in the lineage leading to vertebrates.
Domain Region Specific Sequence Skew: Results of MEME analyses indicate that
the sites with positive dN/dS skew in the PNP1, PNP2 and RPH domains are mostly
located outside α-helices and β-sheets or in other words are in disordered regions of the
domains. In the N-terminal region of the PNP1 protein domain, only two out of ten sites
showing skew are located within β-sheets. These observations are actually consistent
with recent reports that amino acids located in the disordered regions (e.g., random
coils and turns) of protein secondary structure are more likely to be under positive
selective pressure, relative to residues in the more structurally conserved regions like αhelices and β-sheets [150,151]. More specifically, Nilsson and colleagues [150], upon
their examination of the molecular evolution of 3746 genes across 64 strains of budding
yeast (S. cerevisiae, S. paradoxus), concluded that there is a significantly higher degree
of positive Darwinian selection in intrinsically disordered regions compared to alpha
helix, beta sheet or tertiary structures.
In their analysis of 26 protein families, Brown and co-workers concluded that
disordered regions in proteins generally have faster rates of evolution [165]. These
observations are possibly related to the roles disordered regions play in the protein’s
functionality. As Mittag et al explained [166], higher mutation rates in disordered regions
may have been allowed during evolution because sequential modifications within these
regions did not pose severe consequences on protein stability and functionalities.
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Moreover, the disordered regions provide protein flexibility necessary for recognition of
other molecules (such as other proteins and RNAs). This is especially applicable for
proteins such as PNPase and RNase PH, whose target molecules can have a varying
range of secondary and tertiary structures. For PNPase and RNase PH, the need to
adapt to its target molecules is very crucial since the target molecules themselves are
evolving (i.e., mutating) as they adapt to new environment and species physiology.
Another interesting observation in our study is the higher incidence of dN/dS
positive skew in the N-terminus of RPH compared to those of the PNP1 and PNP2. In
the C-termini of the domains, the opposite was evident. The N- and C-termini of proteins
encompass important binding motifs, and it is possible that the termini regions of these
domains, as they diverged during evolution, required different structural modifications
for the different molecules (e.g., helicases or other ribonucleases) they interact with.
Overall, RPH has twice as many positively skewed sites as PNP1 or PNP2. In other
words, RPH has undergone more changes at the molecular level than either PNPase
domain. One possible interpretation is that RPH is evolutionarily more malleable than
the PNPase domains. This perhaps explains the emergence of RPH orthologues in all
kingdoms of life, after it had diverged from the linked PNP domains early on during
organismal evolution [91,93].
Positive skew in codons was also detected in the structurally more complex KH
domain (at numerous positions in α-helices), as well as the S1 domain (at four positions
in the β-sheets at the C-terminus). These events were likely structural refinements that
subsequently aided PNPases in higher organisms as it necessitated them binding to
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newer mRNA and miRNA species. A prime example of this is the human PNPase which
has high specificity for binding and degrading c-myc mRNA and miR-221 [48,49,67,93].
Correlating positive dN/dS skew with mutagenized sites:

There is a direct

correlation between sites chosen for mutagenesis and the loss of function of the
PNPase and RNasePH proteins and an inverse correlation of these sites with positive
dN/dS skew. In general, sites that are important for the function of these proteins as
determined by mutagenesis studies appear to be embedded in regions of the protein
with dN/dS values that are not significantly different from 0.0. This result suggests that
sites adjacent to those currently chosen for mutagenesis studies might also be
appropriate candidates for mutagenesis to study the function of these proteins. There
are two major exceptions to this general trend. The first concerns a region of the PNP2
domain where two serine (S) residues are adjacent to each other. One serine (S484)
has been mutagenized and has been shown to be near a binding site for Citrate D 670
located near the active site of the protein. A site directly adjacent to site S484 (S483)
has positive sequence skew, indicating that this region of PNP2 has some interesting
sequence evolution dynamics involved with it. The second departure from the general
inverse relationship of positive skew with mutagenized sites is at the amino terminus of
the RNasePH domain, where a six amino acid stretch (Y11, R12, D14, G15, R16) has
three residues important for structure of the protein and three residues with positive
dN/dS skew.

	
  

155	
  

	
  
In summary, we present a study that analyzed the molecular events, which have
occurred during the course of evolution of two important RNA degrading enzymes. We
attempted to explain why some regions of the proteins are biased towards positive
dN/dS skew. We have exercised caution in not calling these codons with positive skew
as sites under positive natural selection and in calling codons chosen for mutagenesis
as sites under purifying selection. We do however suggest that the sites we have
identified in this study as skewed are sites that are good candidates for examining the
dynamics of the activity of these proteins. We also suggest that previous choice of sites
for mutagenesis chosen on the basis of extreme conservation, have settled on codons
in regions where surrounding codons have extremely low dN/dS ratios that are for the
most part not significantly different from 0.0. This result suggests that sites adjacent to
those currently in use for mutagenesis studies could be used to expand the repertoire of
tools for studying the functionality of these proteins.
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CHAPTER SIX

General Discussion

Human polynucleotide phosphorylase (hPNPaseold-35) is an evolutionarily
conserved 3’-5’ exoribonuclease [13,91,93]. It has been implicated to play a role in
numerous cellular functions, like growth arrest, apoptosis, senescence associated
degenerative diseases, hearing loss, inflammation, mtRNA import, maintenance of
mitochondrial homeostasis, mtRNA processing and decay. Most of its functions in the
mitochondria are associated with cellular maintenance and routine RNA processing
activities [13,67,93]. As an exoribonuclease in the cytoplasm is has been found to
degrade c-myc mRNA and miR-221 [48,49], which ultimately leads to apoptosis of
cancer cells. Apart from these two mRNA and miRNA species not much is known about
the degradation targets of hPNPaseold-35. These functions of hPNPaseold-35 have been
extensively described in Chapter 1.
The overall aim of this project was to identify degradation targets of hPNPaseold35

other than c-myc and miR-221 and also to further understand the role of hPNPaseold-

35

in the maintenance of cellular homeostasis and this premise has been extensively

dealt with in Chapters 2 and 3. Identification of hPNPaseold-35 targets would help in not
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only furthering our understanding of this protein, but may also provide novel therapeutic
targets for treatment of cancer and other hPNPaseold-35-associated diseases. Another
aspect of this project was to evaluate the evolutionary history of hPNPaseold-35 in
comparison with another RNA degrading enzyme RNasePH, with special focus on the
prediction of functionally important residues under natural selection, mutating which
would hamper the enzymatic activity or RNA binding ability of these proteins. In the
current work (Figure 6.1), we were able to (i) identify hPNPaseold-35- “directly” and
“indirectly” regulated genes in two different overlapping analyses; (ii) demonstrate that
hPNPaseold-35 stable knockdown causes global changes in mitochondrial respiratory
complex and associated genes; (iii) show that hPNPaseold-35 overexpression causes
global changes in cell cycle associated genes; (iv) identify amino acid sites under
positive natural selection in hPNPaseold-35 which could be of potential importance in
mediating its catalytic activity and RNA binding ability.
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Fig. 6.1. Flow chart depicting overall aim of project: to identify degradation targets of
hPNPaseold-35.

In order to identify direct degradation targets of hPNPaseold-35, we performed
microarray analysis on cell lines in which hPNPaseold-35 was overexpressed and
knocked down. In Chapter 2 we used melanoma as a model system to answer these
questions. We were able to identify a number of candidate genes through our
overlapping analysis which could be potential direct or indirect targets of hPNPaseold-35
and were also able to validate the already known involvement of hPNPaseold-35 in
biological processes like mitochondrial respiration and cell cycle arrest with the help of
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pathway analyses tools in IPA (Ingenuity Pathway Analysis). We identified 77 potential
direct targets and validated certain genes like CENPE and MKI67, which are important
for cellular growth and proliferation as being repressed by hPNPaseold-35 by transient
knockdown and overexpression of hPNPaseold-35. Future experiments would involve
verifying the exact mechanism by which hPNPaseold-35 regulates these genes. In vitro
RNA degradation assays would be able to validate if hPNPaseold-35 actually degrades
these transcripts. Other mechanisms of regulation could be more complex and may
involve hPNPaseold-35 –regulated miRNA species targeting genes (like certain
transcription factors), which in turn control the expression of the aforementioned
identified transcripts. To pursue this particular avenue, an analysis of the promoter
regions of the identified direct targets would provide precise knowledge of the
transcription factor (TF) binding elements. If the regulation of the identified targets by a
specific TF has not been reported yet, reporter based assays can be performed to
validate regulation. Finally, a search using the numerous miRNA databases (e.g.
miRBase or TargetScan) can help identify any predicted or validated miRNAs that target
our TF of interest, and even further through RNA degradation assays we can validate if
hPNPaseold-35 regulates that particular miRNA. A similar approach could be used to
validate the mechanism of hPNPaseold-35-regulation of the potential indirect targets
identified like VGF, RNF128 and MCAM, which could probably be regulated by miRNAs
targeted by hPNPaseold-35. In this case we would need to identify miRNA binding sites in
these transcripts by scanning the aforementioned miRNA prediction databases, then
functionally prove that the specific miRNA targets the specific gene by overexpression
or knockdown of the miRNA and finally investigate if hPNPaseold-35 regulates it. Of
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particular interest here is the gene MCAM, which is a cell surface receptor associated
with poor prognosis of melanoma and other cancers [167,168]. hPNPaseold-35
knockdown causes the downregulation of this gene, identifying the mechanism of
hPNPaseold-35-regulation of MCAM (probably via miRNA) may provide valuable
therapeutic opportunities for melanoma treatment [169]. In the same context, VGF
(usually only expressed in nerve cells or neuroendocrine cells) could be promising
candidate too, which is upregulated in lung cancer [170].
In Chapter 3, we extended to identify possible hPNPaseold-35 induced or
repressed genes by performing a similar microarray experiment in HeLa cells following
hPNPaseold-35 overexpression using a doxycycline-inducible expression vector. The
purpose of this additional microarray was to gain perspective relating to hPNPaseold-35
functions in a system other than melanoma and eventually, comparison of two
hPNPaseold-35 datasets in two different cell lines may provide a more global perspective
of hPNPaseold-35 associated gene expression changes. First, in order to identify
hPNPaseold-35 induced or repressed genes, we performed a similar overlapping screen
that we performed in Chapter 2. We used the same melanoma hPNPaseold-35
knockdown dataset we used in Chapter 2, but this time we overlapped it with our HeLa
hPNPaseold-35 dataset rather than with the melanoma. In this analysis we identified 28
repressed and 62 hPNPaseold-35 -induced transcripts. Of special interest here was the
identification of two hPNPaseold-35 -repressed genes CENPE and MKI67, which we also
identified in our melanoma screen. Future experiments would be required to confirm
their direct degradation by hPNPaseold-35 or whether they are downstream/indirect
effects of the downregulation of a key TF like c-myc, which can be validated by myc-
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knockdown experiments. Another interesting hPNPaseold-35 –repressed gene identified
here was CENPA, which was downregulated in three melanoma cell lines upon Ad.
hPNPaseold-35 infection, but levels of which did not change significantly in an
immortalized normal human melanocyte cell line FM516 in preliminary experiments.
CENPA is associated with poor prognosis in breast cancer [134], and thus could prove
to be a potential therapeutic target once we could figure out the mechanism of
hPNPaseold-35 –regulation of this gene, which seems to be indirect as levels of CENPA
did not change in immortalized normal cells. We were also able to identify significant
similar correlations of hPNPaseold-35 expression with a number of the identified induced
and repressed genes in four TCGA datasets we analyzed: colon adenocarcinoma
(COAD), skin cutaneous melanoma (SKCM), ovarian serous cyst adenocarcinoma
(OV), and prostate adenocarcinoma (PRAD). Some of the interesting candidates in this
category were DUSP1, ADARB1 and EMR2, all of which negatively correlate with
hPNPaseold-35 expression and are upregulated in different cancers [136-140]. As
explained earlier as in the case of CENPE, MKI67, VGF, MCAM and CENPA, once the
mechanistic details of the regulation of these genes by hPNPaseold-35 are identified, they
could lead to the discovery of promising therapeutic interventions.
We also compared the gene expression profiles of melanoma and HeLa cells in
which hPNPaseold-35 was overexpressed, and as detailed in Chapter 3, apart from the
fact that almost all the 105 common dysregulated genes identified belonged to cell
cycle-associated gene ontology categories, some of them were also identified as
possible transcriptional targets of c-myc. Therefore, although this analysis provided us
with a gene expression signature of hPNPaseold-35 induced growth arrest, unless we can

	
  

162	
  

	
  
prove otherwise (through RNA degradation assays), it would be difficult to say at this
point whether they are direct targets of hPNPaseold-35 or dysregulated due to changes in
c-myc levels. In order to pursue this avenue further, validation of these genes in a mycnull background would be helpful, which would confirm whether dysregulation of these
genes is caused by hPNPaseold-35 or c-myc.
An alternative approach to validate the directly degraded targets of hPNPaseold-35
identified in Chapters 2 and 3 would be to compare the 3’UTR sequence or secondary
structure of c-myc (a direct degradation target of hPNPaseold-35) with the 3’UTR of these
transcripts and recognize any common elements between them. This may also shed
some light on the conundrum of what is/are the specificity element/s that allows
recognition and subsequent degradation by hPNPaseold-35, a premise dealt with in
Chapter 4. Also, since Ad.hPNPaseold-35 infection causes growth arrest of cancer cells
resulting from degradation of c-myc mRNA with an intact 3’UTR, rescue experiments
involving 3’UTR deletion mutants of c-myc may also help to delineate the region which
may be required for hPNPaseold-35 recognition and degradation.
In Chapter 5, we set out to identify the residues under natural selection in the
different domains of hPNPaseold-35 (PNP1, PNP2, KH and S1) and another closely
related exoribonuclease RNasePH that may be important for their enzymatic activity or
RNA binding ability. The other purpose behind this was that maybe such an
evolutionary analysis would help us identify exactly where in evolutionary history did or
did not hPNPaseold-35 acquire any specificities towards the recognition of certain mRNA
species (like c-myc) versus others. The results provided in Chapter 5 offer in depth
insights into the sequence evolution of hPNPaseold-35 in the vertebrate lineage leading to
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mammals. The residues under positive selection that we identified (extensively
described in Chapter 5) could or could not be involved in the trimer formation,
degradative or binding activities of hPNPaseold-35 and RNasePH. Future work involving
mutation analyses of these sites followed by functional RNA degradation or binding
assays would confirm the importance of these residues in those functions. The eventual
importance of this work lies in understanding the biochemical importance of these
residues, information that provide useful in treating disease states where these may be
mutated or inactivated.
Throughout the course of this dissertation I have tried to explore and understand
the functional implications of hPNPaseold-35 (Figure 6.1). Although our studies have led
to numerous conclusions as detailed in Chapters 2-5, there still remain a number of
unanswered questions that have been discussed in the current chapter. Also, a lot
remains unanswered regarding the biological consequences of hPNPase in normal
versus cancer cells, and animal models with either conditional overexpression or
knockdown of hPNPase will be extremely useful. These models will prove helpful in
understanding the various physiological processes hPNPase is a part of, like mtRNA
import, and will also facilitate studies relating to viral infection, mitochondrial dysfunction
and aging allowing the future development of suitable therapeutics.
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